/**
 * Specialty market demand pages — GSC queries with meaningful impressions
 * outside page one. Content is qualitative intelligence anchored to real
 * regulators, tenders, and care pathways. No fabricated dollar totals.
 */

export type SpecialtyMarketDemandContent = {
  slug: string;
  segmentLabel: string;
  badge: string;
  breadcrumbLabel: string;
  title: string;
  description: string;
  canonical: string;
  h1: string;
  intro: string[];
  hubLink?: { to: string; label: string };
  researchTopics: Array<{ name: string; detail: string }>;
  demandDrivers: { heading: string; drivers: Array<{ title: string; detail: string }> };
  marketStructure: { heading: string; paragraphs: string[] };
  signalGrid?: { heading: string; items: Array<{ label: string; signal: string }> };
  calendarBlocks?: { heading: string; items: Array<{ period: string; detail: string }> };
  audiences: Array<{ audience: string; description: string }>;
  whyBionixus: string[];
  relatedLinks: Array<{ to: string; label: string }>;
  faqs: Array<{ question: string; answer: string }>;
  geoAnswerBlock?: {
    question: string;
    answer: string;
    points: Array<{ title: string; description: string }>;
    summary: string;
  };
  methodologySection?: { heading: string; paragraphs: string[] };
  areaServed?: string[];
  priority: 'now' | 'next' | 'later';
};

const BASE = 'https://www.bionixus.com';

const SHARED_WHY = [
  'Decision-led primary research — not syndicated table dumps',
  'Verified HCP, procurement, and access stakeholder recruitment',
  'Regulator- and pathway-aware study design from protocol one',
  'Comparable instruments for multi-country roll-ups when needed',
  'Board-ready synthesis with evidence gaps and owners flagged',
  '15+ years of healthcare research across 48 countries',
];

/* ------------------------------------------------------------------ */
/* NOW                                                                */
/* ------------------------------------------------------------------ */

const singaporeMedtechManufacturing: SpecialtyMarketDemandContent = {
  slug: 'singapore-medtech-manufacturing-market',
  segmentLabel: 'Singapore MedTech Manufacturing',
  badge: 'Singapore · MedTech Manufacturing',
  breadcrumbLabel: 'Singapore MedTech Manufacturing Market',
  title: 'Singapore MedTech Manufacturing Market Research | BioNixus',
  description:
    'Singapore MedTech manufacturing market intelligence — EDB and JTC manufacturing hubs, HSA manufacturing licences, CDMO capacity, ASEAN export positioning.',
  canonical: `${BASE}/singapore-medtech-manufacturing-market`,
  h1: 'Singapore MedTech Manufacturing Market: Research & Commercial Intelligence',
  intro: [
    'Singapore’s MedTech manufacturing market is not a retail-device story — it is an industrial and export story. Multinationals and Asian OEMs concentrate sterile assembly, implant finishing, diagnostics cartridge production, and contract manufacturing in Jurong, Tuas Biomedical Park, and allied industrial estates because HSA oversight, IP protection, and ASEAN/APAC logistics sit in one jurisdiction. BioNixus runs primary research that turns that manufacturing footprint into commercial decisions: capacity benchmarking, buyer qualification, partner selection, and expansion timing.',
    'Buyers searching “MedTech manufacturing Singapore” and “Singapore MedTech industry” need plant economics, regulatory manufacturing pathways, and hospital/OEM sourcing behaviour — not a generic MedTech market overview. Our programmes interview manufacturing directors, quality leads, procurement at export-focused OEMs, and hospital biomedical engineering teams that specify locally finished devices.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    {
      name: 'Manufacturing footprint & capacity mapping',
      detail:
        'Site-level intelligence on sterile fill-finish, assembly, packaging, and testing capacity across Singapore’s biomedical clusters — including CDMO versus captive OEM models.',
    },
    {
      name: 'HSA manufacturing & quality-system pathways',
      detail:
        'How HSA manufacturing licences, GDPMDS/GDP practices, and quality-system expectations shape time-to-produce and export-dossier readiness.',
    },
    {
      name: 'EDB / JTC investment and expansion signals',
      detail:
        'Incentive and cluster dynamics that change greenfield versus brownfield decisions for Asian and Western MedTech manufacturers.',
    },
    {
      name: 'OEM and hospital buyer qualification',
      detail:
        'What Asian hospital groups and global OEMs demand from Singapore-finished SKUs — documentation depth, dual-source rules, and lead-time reliability.',
    },
    {
      name: 'ASEAN / APAC export routing',
      detail:
        'How Singapore manufacturing is used as a regulatory and logistics springboard into ASEAN, Japan, Korea, Australia, and GCC tenders.',
    },
    {
      name: 'Workforce & cost-to-serve research',
      detail:
        'Talent, wage, and total-cost-to-serve trade-offs versus alternative APAC manufacturing bases — for internal investment committees.',
    },
  ],
  demandDrivers: {
    heading: 'What is driving Singapore MedTech manufacturing demand',
    drivers: [
      {
        title: 'China+1 and supply-risk diversification',
        detail:
          'OEMs and investors are rebalancing sterile and implant manufacturing toward trusted APAC jurisdictions with strong IP and export logistics.',
      },
      {
        title: 'ASEAN device demand growth',
        detail:
          'Hospital expansion across ASEAN raises demand for nearby manufactured SKUs with shorter lead times than EU or US plants.',
      },
      {
        title: 'Diagnostics and implant complexity',
        detail:
          'Cartridge IVD, active implants, and high-precision instruments favour Singapore’s quality and engineering depth.',
      },
      {
        title: 'Regulatory credibility for export',
        detail:
          'HSA-aligned manufacturing documentation supports leaner registration stories in ASEAN and reference-agency reliance pathways.',
      },
      {
        title: 'CDMO outsourcing wave',
        detail:
          'Mid-size MedTech firms prefer Singapore CDMO partners over building greenfield plants for early commercial volumes.',
      },
      {
        title: 'Hospital preference for reliable supply',
        detail:
          'Biomedical engineers and pharmacy buyers weight shortage history and documentation quality when specifying local finishers.',
      },
    ],
  },
  marketStructure: {
    heading: 'How the Singapore MedTech manufacturing market is structured',
    paragraphs: [
      'Singapore’s MedTech manufacturing base clusters around industrial biomedical estates with co-located test labs, sterile suppliers, and specialist logistics. Multinational captives sit alongside Asian OEM affiliates and independent CDMOs. Decision rights for capacity adds typically sit with regional manufacturing directors and global supply-chain committees — not Singapore sales teams alone.',
      'Commercial research must therefore separate three buyer contexts: (1) OEM partner selection for outsourced manufacture, (2) investment-committee diligence on plant expansion, and (3) hospital/public-procurement preference for Singapore-finished SKUs. BioNixus scopes modules to one of those decisions rather than mixing them into an undifferentiated “industry report.”',
      'For manufacturers also selling into Gulf tenders, Singapore manufacturing credentials often travel with the product story — SFDA and MOHAP buyers ask about origin of manufacture, quality system, and dual sources. We link Singapore manufacturing intelligence to GCC access work when that is on the critical path.',
    ],
  },
  signalGrid: {
    heading: 'Singapore manufacturing cluster signals',
    items: [
      {
        label: 'Tuas / Jurong biomedical estates',
        signal:
          'Primary concentration of sterile assembly, packaging, and warehouse-adjacent manufacturing with specialist subcontractor networks.',
      },
      {
        label: 'HSA manufacturing oversight',
        signal:
          'Licence and inspection cadence shapes how fast new lines can serve ASEAN and reference markets.',
      },
      {
        label: 'EDB-supported MedTech investments',
        signal:
          'Incentive and talent programmes keep high-value manufacturing competitive versus lower-cost ASEAN alternatives.',
      },
      {
        label: 'Hospital biomedical engineering buyers',
        signal:
          'Cluster hospitals influence which finished devices earn preferred listing when supply reliability is scored.',
      },
    ],
  },
  audiences: [
    {
      audience: 'Manufacturing & quality directors',
      description: 'Leaders choosing Singapore capacity, CDMO partners, or dual-source strategies.',
    },
    {
      audience: 'OEM and CDMO commercial teams',
      description: 'Firms selling manufacturing slots or finished-device supply into APAC programmes.',
    },
    {
      audience: 'Hospital biomedical engineering & procurement',
      description: 'Stakeholders who qualify Singapore-finished devices for cluster formularies and tenders.',
    },
    {
      audience: 'Investment & corporate development',
      description: 'Teams diligence plant expansions, JV structures, and China+1 manufacturing moves.',
    },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/singapore-medical-devices-market-report', label: 'Singapore medical devices market report' },
    { to: '/pharmaceutical-market-research-singapore', label: 'Pharmaceutical market research Singapore' },
    { to: '/healthcare-market-research-singapore', label: 'Healthcare market research Singapore' },
    { to: '/japan-medical-devices-market-report', label: 'Japan medical devices market report' },
    { to: '/clinical-diagnostics-market-research', label: 'Clinical diagnostics market research' },
  ],
  faqs: [
    {
      question: 'What is the Singapore MedTech manufacturing market?',
      answer:
        'It is the ecosystem of captive OEM plants, CDMOs, and supply-chain partners producing or finishing medical devices and diagnostics in Singapore for domestic use and APAC/ASEAN export — governed by HSA manufacturing rules and clustered in biomedical industrial estates.',
    },
    {
      question: 'Why do MedTech firms manufacture in Singapore?',
      answer:
        'Firms cite IP protection, HSA regulatory credibility, specialist talent, ASEAN logistics, and China+1 diversification. BioNixus validates those claims with plant and buyer interviews rather than brochure narratives.',
    },
    {
      question: 'How does BioNixus research Singapore MedTech manufacturing?',
      answer:
        'We run primary interviews and surveys with manufacturing, quality, OEM commercial, and hospital procurement stakeholders, then map findings to a single investment, partner-selection, or tender decision.',
    },
    {
      question: 'Can Singapore manufacturing research link to GCC tenders?',
      answer:
        'Yes. Origin-of-manufacture and quality-system evidence often travels into SFDA and MOHAP tender dossiers; BioNixus connects Singapore manufacturing modules to GCC market-access research when needed.',
    },
  ],
  areaServed: ['Singapore'],
  priority: 'now',
};

const singaporePharmaceuticalMarket: SpecialtyMarketDemandContent = {
  slug: 'singapore-pharmaceutical-market',
  segmentLabel: 'Singapore Pharmaceutical Market',
  badge: 'Singapore · Pharmaceuticals',
  breadcrumbLabel: 'Singapore Pharmaceutical Market',
  title: 'Singapore Pharmaceutical Market Intelligence 2026 | BioNixus',
  description:
    'Singapore pharmaceutical market intelligence — HSA registration, ACE HTA, MOH SDL/MAF subsidy listing, SingHealth/NUHS/NHG cluster dynamics, and APAC hub.',
  canonical: `${BASE}/singapore-pharmaceutical-market`,
  h1: 'Singapore Pharmaceutical Market: Structure, Access & Commercial Intelligence',
  intro: [
    'The Singapore pharmaceutical market is small by population but outsized as an APAC headquarters, regulatory, and access proving ground. HSA registration opens the door; ACE appraisal and MOH Standard Drug List / Medication Assistance Fund decisions determine whether products are affordable in public care. BioNixus delivers market intelligence that separates hub optics from real cluster uptake — so commercial teams do not mistake Singapore HQ presence for market share.',
    'Search for “Singapore pharma market” usually signals sizing, access sequencing, and competitor mapping needs. Our programmes combine desk structure with primary physician, pharmacy, and access interviews across SingHealth, NUHS, and NHG — then link findings to ASEAN or GCC expansion where that is the real P&L question.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    {
      name: 'Market structure & channel mix',
      detail:
        'Public cluster versus private specialty share, hospital-administered versus retail pathways, and where volume actually concentrates by therapy area.',
    },
    {
      name: 'HSA → ACE → MOH subsidy pathway',
      detail:
        'Evidence and timing map from registration through ACE cost-effectiveness to SDL/MAF listing decisions that unlock public uptake.',
    },
    {
      name: 'Cluster formulary behaviour',
      detail:
        'How SingHealth, NUHS, and NHG evaluate oncology, immunology, and chronic-care brands beyond national subsidy lists.',
    },
    {
      name: 'APAC hub commercial intelligence',
      detail:
        'Separating Singapore HQ and medical-affairs footprint from in-market prescribing and tender wins.',
    },
    {
      name: 'Competitor and analogue mapping',
      detail:
        'Brand, biosimilar, and therapeutic-class analogues with access and message implications.',
    },
    {
      name: 'ASEAN / GCC sequencing briefs',
      detail:
        'When Singapore evidence travels usefully to Malaysia, Indonesia, or Gulf access dossiers — and when it does not.',
    },
  ],
  demandDrivers: {
    heading: 'Forces shaping the Singapore pharmaceutical market',
    drivers: [
      {
        title: 'Subsidy-gated public uptake',
        detail:
          'SDL/MAF and financing schemes (MediShield Life, MediSave, CHAS) dominate affordability in public pathways.',
      },
      {
        title: 'ACE health-technology assessment',
        detail:
          'Cost-effectiveness expectations set the evidence bar before national funding conversations advance.',
      },
      {
        title: 'Cluster hospital concentration',
        detail:
          'High specialty volumes concentrate in a small set of public institutions — account strategy matters.',
      },
      {
        title: 'APAC headquarters density',
        detail:
          'Regional medical and commercial roles inflate presence indicators unless primary research corrects them.',
      },
      {
        title: 'Oncology and specialty growth',
        detail:
          'High-cost classes drive most strategic briefs BioNixus fields from multinational sponsors.',
      },
      {
        title: 'Reference-market spillover',
        detail:
          'Singapore access narratives are reused in ASEAN and sometimes GCC strategy debates — correctly or not.',
      },
    ],
  },
  marketStructure: {
    heading: 'How the Singapore pharmaceutical market works in practice',
    paragraphs: [
      'Public clusters dominate specialty care; private specialists and retail pharmacies matter more in primary and elective categories. Registration without subsidy listing often strand brands in a narrow cash-pay or private channel. BioNixus therefore treats ACE and MOH subsidy context as commercial structure — not regulatory trivia.',
      'Because Singapore is frequently the first Asian dossier or APAC medical hub, global teams ask for “market size” answers that should really be framed as access-gated uptake scenarios. We deliver scenario structure with primary validation rather than a single invented total.',
    ],
  },
  signalGrid: {
    heading: 'Access and care-delivery signals',
    items: [
      {
        label: 'HSA registration',
        signal: 'Necessary but rarely sufficient for public-volume commercial success.',
      },
      {
        label: 'ACE appraisal',
        signal: 'Evidence and economic narrative gate that shapes MOH funding conversations.',
      },
      {
        label: 'SDL / MAF listing',
        signal: 'Main public affordability switch for many chronic and specialty products.',
      },
      {
        label: 'Cluster formularies',
        signal: 'SingHealth, NUHS, and NHG still impose product-level and protocol filters.',
      },
    ],
  },
  audiences: [
    {
      audience: 'Specialist physicians & KOLs',
      description: 'Oncology, immunology, cardiometabolic, and rare-disease leaders driving protocol choice.',
    },
    {
      audience: 'Hospital pharmacy & formulary committees',
      description: 'Cluster stakeholders who convert national listing into ward and clinic use.',
    },
    {
      audience: 'Access / HEOR & medical affairs',
      description: 'Teams building ACE and subsidy dossiers and payer narratives.',
    },
    {
      audience: 'APAC commercial leadership',
      description: 'Regional leads sequencing Singapore versus ASEAN and GCC investments.',
    },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/pharmaceutical-market-research-singapore', label: 'Pharmaceutical market research Singapore' },
    { to: '/healthcare-market-research-singapore', label: 'Healthcare market research Singapore' },
    { to: '/singapore-medtech-manufacturing-market', label: 'Singapore MedTech manufacturing market' },
    { to: '/singapore-medical-devices-market-report', label: 'Singapore medical devices market report' },
    { to: '/pharmaceutical-market-research-japan', label: 'Pharmaceutical market research Japan' },
    { to: '/healthcare-market-research', label: 'Healthcare market research hub' },
  ],
  faqs: [
    {
      question: 'How large is the Singapore pharmaceutical market?',
      answer:
        'Singapore’s pharmaceutical market is moderated by population size but concentrated in high-value specialty care and public-subsidy pathways. BioNixus sizes categories from access-gated uptake and primary stakeholder research rather than publishing a single unaudited national total as fact.',
    },
    {
      question: 'What determines real access in Singapore?',
      answer:
        'HSA registration, ACE appraisal, MOH SDL/MAF subsidy decisions, financing scheme design, and cluster formulary behaviour all matter. Research should map that sequence for each brand, not stop at registration.',
    },
    {
      question: 'How is this page different from BioNixus pharmaceutical market research Singapore?',
      answer:
        'This page is market-structure and access intelligence for the “Singapore pharmaceutical market” query. /pharmaceutical-market-research-singapore is the BOFU service page for commissioning Singapore fieldwork programmes.',
    },
  ],
  areaServed: ['Singapore'],
  priority: 'now',
};

const japanGeneralSurgicalDevices: SpecialtyMarketDemandContent = {
  slug: 'japan-general-surgical-devices-market',
  segmentLabel: 'Japan General Surgical Devices',
  badge: 'Japan · Surgical Devices',
  breadcrumbLabel: 'Japan General Surgical Devices Market',
  title: 'Japan General Surgical Devices Market Research | BioNixus',
  description:
    'Japan general surgical devices market intelligence — OR procurement, PMDA pathways, NHI functional classification, laparoscopy and energy devices, and.',
  canonical: `${BASE}/japan-general-surgical-devices-market`,
  h1: 'Japan General Surgical Devices Market: Research & Commercial Intelligence',
  intro: [
    'Japan’s general surgical devices market sits inside the world’s third-largest medical device economy — with OR adoption shaped by PMDA classification, NHI functional category pricing, and hospital capital planning rather than US-style IDN contracts alone. BioNixus researches stapler, energy, laparoscopy, clip, and open-surgery instrument decisions with surgeons, OR nurses, and hospital procurement so launch teams know which accounts move volume.',
    'Generic “Japan medical devices” reports bury general surgery inside imaging and endoscopy giants. This page isolates the surgical-instruments and OR consumables decision set so OEMs can brief Japan without competing for attention against MRI and endoscopy headlines.',
    'Surgeon preference in Japan is socially transmitted through university-hospital training networks and distributor clinical-specialist relationships. A product win at a Tokyo university centre can cascade to community ORs — but only when nurse workflow, service contracts, and NHI category economics align. BioNixus maps that cascade rather than treating Japan as a single national panel.',
    'Capital versus consumable procurement cycles differ materially: energy platforms and advanced staplers follow multi-year evaluation, while high-volume clips and basic laparoscopic SKUs refresh on annual tender rhythms. Forecasts that ignore that split systematically overstate near-term share capture.',
    'BioNixus proposals for Japan general surgery are scoped to a single SKU cluster and decision type so fieldwork stays actionable for affiliate commercial and medical teams.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    {
      name: 'OR adoption & technique migration',
      detail:
        'Laparoscopic versus open vs robotic-adjacent instrument use, and what changes stapling, energy, and clip preference.',
    },
    {
      name: 'Hospital procurement & capital cycles',
      detail:
        'How Japanese hospitals score price, service contracts, training burden, and total cost of ownership for general surgery SKUs.',
    },
    {
      name: 'PMDA class & predicate strategy',
      detail:
        'Classification and clinical-evidence expectations that shape Japan entry timing for new surgical platforms.',
    },
    {
      name: 'NHI category pricing implications',
      detail:
        'Functional classification effects on reusable versus disposable strategy and premium claims.',
    },
    {
      name: 'Competitive objection libraries',
      detail:
        'Surgeon and nurse switch barriers across Olympus-adjacent workflows and multinational stapling/energy portfolios.',
    },
    {
      name: 'Training & KOL cascade mapping',
      detail:
        'Which university hospitals and high-volume community ORs actually set technique norms regionally.',
    },
  ],
  demandDrivers: {
    heading: 'Demand drivers in Japan general surgical devices',
    drivers: [
      {
        title: 'Aging surgical volumes',
        detail: 'Older-patient procedure mix lifts demand for efficient, low-complication general surgery workflows.',
      },
      {
        title: 'Minimally invasive migration',
        detail: 'Ongoing laparoscopy and energy-device substitution reframes stapler and instrument baskets.',
      },
      {
        title: 'Device-lag reduction',
        detail: 'Faster PMDA pathways make concurrent Japan launches more realistic for innovative platforms.',
      },
      {
        title: 'Hospital cost pressure',
        detail: 'Procurement committees intensify TCO and service-contract scrutiny on OR consumables.',
      },
      {
        title: 'Domestic OEM strength',
        detail: 'Japanese manufacturers remain influential referents in surgeon preference research.',
      },
      {
        title: 'Training bottleneck',
        detail: 'OR nurse and surgeon training bandwidth gates how fast new platforms spread beyond KOLs.',
      },
    ],
  },
  marketStructure: {
    heading: 'Market structure for general surgical devices in Japan',
    paragraphs: [
      'Japan’s hospital density and NHI coverage create high baseline procedure volume, but SKU choice concentrates in university and high-volume community hospitals first. Distributors and manufacturer clinical specialists jointly shape OR familiarity; service and training often decide switches as much as stapling performance claims.',
      'BioNixus designs Japan general surgery programmes around a single decision — launch sequencing, competitive defence, or portfolio rationalisation — then recruits surgeons, OR nurses, biomedical engineers, and procurement with verified practice settings.',
      'Capital versus consumable mix differs by category: energy platforms and robotic-adjacent instruments carry longer evaluation cycles, while clips and basic laparoscopic SKUs turn over on tender calendars. Misreading that mix produces forecasts that look precise but miss the procurement gate that actually binds uptake.',
      'BioNixus standard Japan general surgery deliverables include a tiered hospital account map, a competitive objection library by SKU category, and a fiscal-year procurement calendar aligned to OR capital and consumable refresh cycles.',
      'Global portfolio teams should begin Japan fieldwork once PMDA classification is clear — waiting until post-shonin launch windows often means incumbent contracts already locked for the fiscal year.',
    ],
  },
  calendarBlocks: {
    heading: '2026 Japan general surgery commercial checkpoints',
    items: [
      {
        period: 'Q1 — fiscal-year capital planning',
        detail:
          'Japanese hospitals lock OR capital and major consumable frameworks around fiscal-year boundaries. Run procurement and surgeon interviews before committees freeze vendor shortlists.',
      },
      {
        period: 'Q2 — technique-migration fieldwork',
        detail:
          'Peak congress and training season — ideal window for KOL cascade mapping and competitive objection libraries on energy and stapling platforms.',
      },
      {
        period: 'Q3 — mid-year tender defence',
        detail:
          'Community hospitals refresh high-volume SKU contracts. Test TCO, service-contract, and nurse-workflow narratives with biomedical engineering stakeholders.',
      },
      {
        period: 'Q4 — 2027 launch sequencing',
        detail:
          'Global portfolio teams align Japan PMDA/NHI timelines with 2027 OR budgets. Scenario-plan competitive responses before loss-of-exclusivity or new-platform windows.',
      },
    ],
  },
  signalGrid: {
    heading: 'Category signals',
    items: [
      { label: 'Energy & advanced dissection', signal: 'Technique migration hotspot with training-heavy adoption curves.' },
      { label: 'Stapling & clip systems', signal: 'High volume; loyalty tied to OR familiarity and complication risk.' },
      { label: 'Laparoscopic instruments', signal: 'Capex plus disposable mix; committee TCO scrutiny rising.' },
      { label: 'Open surgery instrumentation', signal: 'Still material in community hospitals and selected case types.' },
    ],
  },
  audiences: [
    { audience: 'General & MIS surgeons', description: 'Procedure owners who decide platform familiarity and brand loyalty.' },
    { audience: 'OR nursing leads', description: 'Workflow and setup stakeholders who make or break adoption.' },
    { audience: 'Hospital procurement / VAS', description: 'Committees scoring price, service, and standardization.' },
    { audience: 'Biomedical engineering', description: 'Maintenance, capital, and inventory gatekeepers.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/japan-medical-devices-market-report', label: 'Japan medical devices market report' },
    { to: '/pharmaceutical-market-research-japan', label: 'Pharmaceutical market research Japan' },
    { to: '/healthcare-market-research-japan', label: 'Healthcare market research Japan' },
    { to: '/singapore-medtech-manufacturing-market', label: 'Singapore MedTech manufacturing market' },
    { to: '/gcc-anesthesia-surgical-market-report', label: 'GCC anesthesia & surgical market report' },
  ],
  faqs: [
    {
      question: 'What is included in the Japan general surgical devices market?',
      answer:
        'Typically staplers, energy devices, clips, laparoscopic instruments, and related OR consumables/capital — excluding bulk imaging and endoscopy capital systems that dominate broader “medical devices” headlines.',
    },
    {
      question: 'How does NHI affect surgical device choice in Japan?',
      answer:
        'Devices map into functional reimbursement categories; premiums for genuine innovation require clear clinical differentiation. BioNixus researches how those category dynamics influence hospital standardization decisions.',
    },
    {
      question: 'Does BioNixus recruit Japanese surgeons for device research?',
      answer:
        'Yes — verified surgeons, OR nurses, and procurement stakeholders, with instruments designed for Japanese hospital workflow and reporting suitable for global portfolio committees.',
    },
    {
      question: 'What is the Japan general surgical devices market size in 2026?',
      answer:
        'General surgical instruments and OR consumables represent a material slice of Japan’s ~$41B medical device economy — distinct from imaging and endoscopy capital. BioNixus sizes addressable decision cells (stapling, energy, laparoscopy, clips) with primary hospital research rather than syndicated headline totals that bury surgery inside “medical devices.”',
    },
    {
      question: 'How do PMDA pathways differ for surgical devices versus drugs?',
      answer:
        'PMDA classifies devices by risk (Class I notification through Class IV shonin). Predicate and clinical-data expectations vary by category; energy and novel stapling platforms may require clinical evidence beyond todokede routes. BioNixus maps classification and evidence expectations before launch sequencing workshops.',
    },
    {
      question: 'Which Japanese hospital types drive general surgery volume first?',
      answer:
        'University hospitals and designated advanced-care centres set technique norms that cascade to high-volume community ORs. BioNixus tiers accounts by referral influence and procedure volume — not bed count alone — when designing surgeon and nurse quotas.',
    },
    {
      question: 'Can BioNixus support competitive defence against domestic Japanese OEMs?',
      answer:
        'Yes — objection libraries, service-contract comparisons, and nurse-workflow research clarify where multinational platforms win despite domestic incumbents — and where training burden or distributor relationships block switching.',
    },
    {
      question: 'How do distributor relationships shape Japan surgical device share?',
      answer:
        'Major distributors and manufacturer clinical specialists co-own OR relationships — training schedules, service response, and surgeon access often outweigh marginal product performance differences. BioNixus maps distributor influence alongside surgeon preference when designing competitive modules.',
    },
    {
      question: 'What training burden blocks laparoscopic platform switches in Japan?',
      answer:
        'OR nurse setup time, instrument compatibility with existing towers, and surgeon proctoring requirements create inertia even when new platforms show clinical advantages. BioNixus quantifies training and workflow friction with nursing and surgeon stakeholders before launch forecasts assume rapid share capture.',
    },
    {
      question: 'How should OEMs time Japan general surgery research around PMDA approval?',
      answer:
        'Begin surgeon and procurement interviews once classification and evidence requirements are clear — not after shonin when hospital committees are already locked into incumbent contracts. Pre-approval research informs launch sequencing, KOL mapping, and distributor strategy simultaneously.',
    },
    {
      question: 'Does BioNixus link Japan surgical research to GCC expansion plans?',
      answer:
        'Yes — teams entering Gulf OR markets after Japan launches often reuse technique-migration and training-burden learnings. We offer comparative modules across Japan and GCC anesthesia/surgical reports when portfolio committees need cross-regional evidence.',
    },
    {
      question: 'How do robotic-adjacent platforms affect general surgical device baskets?',
      answer:
        'Robotic programmes reshape stapler, energy, and clip preferences in high-volume centres — but community hospitals may lag for years. BioNixus segments robotic-adjacent accounts from standard MIS/community ORs so forecasts do not assume uniform technique migration.',
    },
    {
      question: 'What service-contract terms matter in Japan OR device renewals?',
      answer:
        'Response time, clinical specialist coverage, loaner instrument availability, and nurse training refresh are scored alongside price in renewal tenders. BioNixus researches biomedical engineering and OR nursing stakeholders on service satisfaction — not just surgeon brand preference.',
    },
    {
      question: 'How does BioNixus sample Japanese surgeons for device research?',
      answer:
        'Quotas reflect procedure volume, institution tier, and technique mix — MIS versus open, robotic-adjacent versus standard laparoscopy — with verified practice settings. Instruments mirror realistic case types and escalation sequences clinicians actually debate in OR committees.',
    },
  ],
  areaServed: ['Japan'],
  geoAnswerBlock: {
    question: 'What is the Japan general surgical devices market in 2026?',
    answer:
      'Japan’s general surgical devices market covers staplers, energy devices, laparoscopic instruments, clips, and OR consumables inside the world’s third-largest medical device economy — shaped by PMDA classification, NHI functional pricing, and hospital capital cycles. BioNixus researches surgeons, OR nurses, and procurement committees for launch, defence, and portfolio decisions.',
    points: [
      {
        title: 'OR adoption & technique migration',
        description:
          'Laparoscopic versus open versus robotic-adjacent workflows reshape stapling, energy, and clip preferences by hospital tier.',
      },
      {
        title: 'PMDA & NHI context',
        description:
          'Classification and functional reimbursement categories determine reusable versus disposable strategy and premium claims.',
      },
      {
        title: 'Procurement & TCO scrutiny',
        description:
          'Hospital committees score service contracts, training burden, and nurse workflow alongside product performance.',
      },
      {
        title: 'KOL cascade mapping',
        description:
          'University hospitals set technique norms that cascade to community ORs when distributor and training support align.',
      },
    ],
    summary:
      'Request a Japan general surgical devices research briefing through BioNixus contact — scoped to launch sequencing or competitive defence.',
  },
  methodologySection: {
    heading: 'How BioNixus researches Japan general surgical devices',
    paragraphs: [
      'Engagements anchor on one decision — launch sequencing, competitive defence, or portfolio rationalisation — and one SKU cluster such as energy, stapling, laparoscopy, or clips. That focus avoids unfocused “Japan medtech” interviews that do not move share.',
      'Surgeon, OR nurse, biomedical engineering, and procurement quotas reflect verified practice setting and procedure volume — university hub versus high-volume community OR — not honorific titles alone.',
      'Modules capture training burden, service-contract satisfaction, distributor influence, and NHI category economics alongside product performance claims. Fiscal-year capital and consumable calendars inform when evidence packs must be ready for committee review.',
      'Deliverables include tiered account maps, competitive objection libraries, KOL cascade diagrams, and procurement calendars aligned to Japanese hospital budgeting. Leadership synthesis links findings to affiliate commercial, medical, and access owners on the same planning cycle.',
      'Cross-link to the Japan medical devices market report and GCC anesthesia surgical report when portfolio teams need APAC–Gulf comparative evidence.',
      'Contact BioNixus for a scoped Japan general surgical devices research proposal — typically delivered within planning cycles affiliates align to fiscal-year OR budgets and PMDA registration milestones.',
    ],
  },
  priority: 'now',
};

const healthcareBioconvergence: SpecialtyMarketDemandContent = {
  slug: 'healthcare-bioconvergence-market',
  segmentLabel: 'Healthcare Bioconvergence',
  badge: 'Global · Bioconvergence',
  breadcrumbLabel: 'Healthcare Bioconvergence Market',
  title: 'Healthcare Bioconvergence Market Research | BioNixus',
  description:
    'Healthcare bioconvergence market research — where biotech, MedTech, digital health, and materials science converge. Stakeholder mapping, partnership.',
  canonical: `${BASE}/healthcare-bioconvergence-market`,
  h1: 'Healthcare Bioconvergence Market: Research for Converging Life-Science Platforms',
  intro: [
    'Healthcare bioconvergence is the commercial meeting point of biology, engineering, computing, and materials — from bioelectronic medicine and tissue engineering to AI-enabled diagnostics and cell-device combination platforms. Buyers searching this term need partnership maps, evidence pathways, and buyer readiness — not a glossary essay. BioNixus runs primary research with clinicians, hospital innovation offices, regulators’ adjacent advisors, and corporate BD teams to test where bioconvergence products actually clear hospital and access gates.',
    'Because the category straddles drugs, devices, and software, generic MedTech or pharma reports miss the decision rights. Our programmes frame one decision first — partner selection, indication prioritisation, or hospital adoption — then recruit the stakeholders who hold that decision.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    {
      name: 'Hospital innovation & adoption research',
      detail:
        'How academic medical centres and private hospital groups evaluate bioconvergence pilots versus standard of care.',
    },
    {
      name: 'Partnership and BD diligence interviews',
      detail:
        'What pharma, MedTech, and tech buyers require before term sheets for platform or asset partnerships.',
    },
    {
      name: 'Regulatory pathway mapping',
      detail:
        'Drug-device, SaMD, and combination-product evidence expectations across US, EU, GCC, and APAC reference markets.',
    },
    {
      name: 'Clinician workflow readiness',
      detail:
        'Training, infra, and care-pathway friction that stalls deployments after technical proof-of-concept.',
    },
    {
      name: 'Payer and value narrative tests',
      detail:
        'Whether health systems and payers treat bioconvergence offerings as devices, procedures, or high-cost therapies.',
    },
    {
      name: 'Cluster / ecosystem benchmarking',
      detail:
        'Competitive positioning across Singapore, Israel, Boston, and Gulf innovation hubs for corporate investment committees.',
    },
  ],
  demandDrivers: {
    heading: 'Why bioconvergence is on commercial agendas now',
    drivers: [
      {
        title: 'Platform valuation pressure',
        detail: 'Investors demand hospital and partnership evidence earlier in asset timelines.',
      },
      {
        title: 'Hospital digital & device fusion',
        detail: 'OR, ICU, and diagnostics workflows now assume software-plus-biology stacks.',
      },
      {
        title: 'Combination-product pipelines',
        detail: 'More assets require dual drug-device regulatory and access stories.',
      },
      {
        title: 'Asia hub competition',
        detail: 'Singapore and other APAC hubs compete for manufacturing and clinical partners.',
      },
      {
        title: 'Gulf innovation tenders',
        detail: 'Vision 2030-era health megaprojects create early-adopter hospital opportunities.',
      },
      {
        title: 'AI diagnostics regulation',
        detail: 'Clearer SaMD rules make commercial timelines more plannable — and diligence more rigorous.',
      },
    ],
  },
  marketStructure: {
    heading: 'How to research a bioconvergence market without false precision',
    paragraphs: [
      'Bioconvergence is a lens, not a single SKU class. Credible research segments by use case — regenerative implants, bioelectronics, AI pathology, cell-device delivery — then maps buyers accordingly. BioNixus does not invent a global dollar total for “the bioconvergence market”; we size addressable decision cells with primary validation.',
      'Corporate teams typically need three deliverables: (1) a stakeholder map with decision rights, (2) evidence-gap and pathway implications, and (3) a partner shortlist with interview-backed fit criteria. That is the shape of our standard briefing.',
    ],
  },
  audiences: [
    {
      audience: 'Hospital innovation & clinical champions',
      description: 'Stakeholders who pilot or block new platforms inside health systems.',
    },
    {
      audience: 'Pharma / MedTech BD and strategy',
      description: 'Teams diligence-ing partnerships, options, and geographic bets.',
    },
    {
      audience: 'Regulators-adjacent advisors & KOLs',
      description: 'Experts who shape evidence expectations for combination and SaMD pathways.',
    },
    {
      audience: 'Investors & corporate development',
      description: 'Capital allocators needing primary market reality checks.',
    },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/singapore-medtech-manufacturing-market', label: 'Singapore MedTech manufacturing market' },
    { to: '/clinical-diagnostics-market-research', label: 'Clinical diagnostics market research' },
    { to: '/real-world-evidence', label: 'Real world evidence' },
    { to: '/healthcare-market-research', label: 'Healthcare market research hub' },
    { to: '/bionixus-industries', label: 'BioNixus industries hub' },
    { to: '/japan-medical-devices-market-report', label: 'Japan medical devices market report' },
  ],
  faqs: [
    {
      question: 'What is healthcare bioconvergence?',
      answer:
        'It is the commercial and R&D convergence of biology with engineering, computing, and materials — spanning bioelectronics, regenerative platforms, AI diagnostics, and combination products that sit between classic pharma and MedTech categories.',
    },
    {
      question: 'How large is the healthcare bioconvergence market?',
      answer:
        'Published “global totals” often mix incompatible asset classes. BioNixus scopes addressable opportunity by use case and buyer pathway with primary research rather than quoting a single unverifiable headline.',
    },
    {
      question: 'Who buys bioconvergence products?',
      answer:
        'Depending on the asset: hospital innovation offices, specialty clinical departments, payers via procedure or high-cost therapy pathways, and corporate BD partners — rarely a single procurement lane.',
    },
  ],
  priority: 'now',
};

const nupcoTenderCalendar: SpecialtyMarketDemandContent = {
  slug: 'nupco-tender-calendar-events-2026',
  segmentLabel: 'NUPCO Tender Calendar 2026',
  badge: 'Saudi Arabia · NUPCO',
  breadcrumbLabel: 'NUPCO Tender Calendar & Events 2026',
  title: 'NUPCO Tender Calendar & Events 2026 | BioNixus',
  description:
    'NUPCO tender calendar and events planning for 2026 — framework-agreement cycles, conference timing, hospital pull-through signals, and primary research.',
  canonical: `${BASE}/nupco-tender-calendar-events-2026`,
  h1: 'NUPCO Tender Calendar & Events 2026: Planning Intelligence for Saudi Access Teams',
  intro: [
    'NUPCO remains the Kingdom’s central procurement spine for MOH and a widening set of public facilities. Teams searching “NUPCO tender conference” or “NUPCO event 2026” usually need timing discipline — when framework agreements refresh, when supplier events concentrate, and when hospital pull-through research should land — not a PDF of every lot number. BioNixus publishes planning intelligence that connects the tender calendar to commercial fieldwork.',
    'Use this page with our deeper NUPCO tendering guide for process mechanics, then commission primary research for molecule- or category-specific award strategy. Calendar statements should always be revalidated against NUPCO’s live notices before bid decisions.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    {
      name: 'Framework-agreement cycle tracking',
      detail:
        'Therapeutic-area framework timing, pre-qualification windows, and when hospital demand pull materialises after listing.',
    },
    {
      name: 'Event & conference calendar mapping',
      detail:
        'Supplier forums, sector conferences, and Saudi access events where NUPCO-facing conversations concentrate in 2026.',
    },
    {
      name: 'Category readiness assessments',
      detail:
        'Whether your SKU’s ICV, supply, and clinical-evidence story is ready before the next relevant framework window.',
    },
    {
      name: 'Hospital pull-through research',
      detail:
        'Post-award interviews that explain why listed products convert — or stall — inside MOH and affiliated hospitals.',
    },
    {
      name: 'Competitor award surveillance',
      detail:
        'Win/loss themes and messaging patterns from recent analogous awards for commercial war-rooms.',
    },
    {
      name: 'ICV & localization diligence',
      detail:
        'How In-Country Value expectations are scoring in live categories your team intends to chase.',
    },
  ],
  demandDrivers: {
    heading: 'Why calendar discipline matters for NUPCO categories',
    drivers: [
      {
        title: 'Framework shift since 2024',
        detail: 'Demand-driven frameworks changed volume timing versus legacy fixed-quantity awards.',
      },
      {
        title: 'Vision 2030 localization',
        detail: 'ICV scoring makes readiness windows more decisive than price alone.',
      },
      {
        title: 'Event-driven networking',
        detail: 'Supplier and hospital forums still cluster key relationship cycles into calendar peaks.',
      },
      {
        title: 'Category clustering',
        detail: 'Oncology, biosimilars, and high-volume injectables move on distinct framework cadences.',
      },
      {
        title: 'Evidence requirements rising',
        detail: 'Budget-impact and clinical-confidence docs need runway before portals open.',
      },
      {
        title: 'Affiliate bandwidth',
        detail: 'Global teams miss Saudi windows without a shared planning calendar.',
      },
    ],
  },
  marketStructure: {
    heading: 'How to use a NUPCO calendar without treating it as legal advice',
    paragraphs: [
      'Official tender notices, e-procurement portals, and NUPCO communications remain authoritative. This page is commercial planning intelligence — BioNixus translates typical seasonal patterns, category clustering, and event timing into research calendars for access and business-development teams.',
      'For process depth — bidder registration, document packs, and award mechanics — start with the NUPCO Saudi Arabia tendering guide, then return here for 2026 planning checkpoints and research module timing.',
    ],
  },
  calendarBlocks: {
    heading: '2026 NUPCO planning checkpoints (indicative)',
    items: [
      {
        period: 'Q1 2026 — readiness & pre-qualification',
        detail:
          'Confirm documentation packs, ICV narratives, and sample hospital references before major framework refreshes. Commission win/loss interviews on prior analogous awards.',
      },
      {
        period: 'Q2 2026 — framework & supplier-forum season',
        detail:
          'Peak period for many therapeutic-area conversations and industry events. Run live competitive-message testing with pharmacy and procurement while windows are open.',
      },
      {
        period: 'Q3 2026 — hospital pull-through',
        detail:
          'Measure whether framework placement converts to ward and formulary use. Identify bottlenecks in distribution, clinician confidence, or substitution rules.',
      },
      {
        period: 'Q4 2026 — portfolio & 2027 sequencing',
        detail:
          'Re-forecast volumes and lock 2027 evidence and localization investments against expected framework cycles.',
      },
    ],
  },
  audiences: [
    {
      audience: 'Market access & tender leads',
      description: 'Owners of NUPCO strategy, documentation, and award reviews.',
    },
    {
      audience: 'Hospital pharmacy stakeholders',
      description: 'Influencers of post-award substitution and consumption.',
    },
    {
      audience: 'Local partners & distributors',
      description: 'Execution partners who need shared calendar and evidence packs.',
    },
    {
      audience: 'Global affiliate commercial teams',
      description: 'Regional leads aligning Saudi windows with global launch calendars.',
    },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/blog/nupco-saudi-arabia-tendering-guide', label: 'NUPCO Saudi Arabia tendering guide' },
    { to: '/gcc-market-access-guide', label: 'GCC pharmaceutical market access guide' },
    { to: '/sfda-market-access-strategy-saudi-arabia', label: 'SFDA market access strategy Saudi Arabia' },
    { to: '/healthcare-market-research/saudi-arabia', label: 'Healthcare market research Saudi Arabia' },
    { to: '/gcc-generic-injectables-market', label: 'GCC generic injectables market' },
    { to: '/market-research-saudi-arabia-pharmaceutical', label: 'Market research Saudi Arabia pharmaceutical' },
  ],
  faqs: [
    {
      question: 'Where can I find the official NUPCO tender calendar for 2026?',
      answer:
        'Always rely on NUPCO’s official portals and notices for lot-level dates. BioNixus provides planning intelligence and primary research around typical cycles and events — not a substitute for official procurement documents.',
    },
    {
      question: 'Is this the same as the NUPCO tendering guide?',
      answer:
        'No. The blog tendering guide explains how NUPCO processes work. This page focuses on 2026 calendar and event planning plus when to run commercial research around those windows.',
    },
    {
      question: 'Can BioNixus support a specific NUPCO category?',
      answer:
        'Yes. We design category-specific win/loss, ICV diligence, and hospital pull-through modules timed to your framework windows.',
    },
  ],
  areaServed: ['Saudi Arabia'],
  priority: 'now',
};

/* ------------------------------------------------------------------ */
/* NEXT                                                               */
/* ------------------------------------------------------------------ */

const singaporeIvdMarketAccess: SpecialtyMarketDemandContent = {
  slug: 'singapore-ivd-market-access',
  segmentLabel: 'Singapore IVD Market Access',
  badge: 'Singapore · IVD Access',
  breadcrumbLabel: 'Singapore IVD Market Access',
  title: 'Singapore IVD Market Access Research | BioNixus',
  description:
    'Singapore IVD market access research — HSA device pathways, hospital lab procurement, cluster testing algorithms, and reimbursement-adjacent adoption.',
  canonical: `${BASE}/singapore-ivd-market-access`,
  h1: 'Singapore IVD Market Access: Lab, Hospital & Regulatory Intelligence',
  intro: [
    'IVD market access in Singapore is won inside hospital laboratories and cluster testing algorithms as much as at HSA registration. BioNixus researches pathologists, lab directors, and procurement committees to show which assays clear volume barriers — and which stall as “registered but unused.”',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'Lab director & pathologist interviews', detail: 'Algorithm fit, turnaround, and trust barriers for new assays.' },
    { name: 'HSA IVD pathway mapping', detail: 'Classification and evidence expectations for commercial sequencing.' },
    { name: 'Cluster lab procurement', detail: 'SingHealth / NUHS / NHG tender and standardization logic.' },
    { name: 'Competitive installed-base research', detail: 'Analyser platforms and switching costs that lock share.' },
    { name: 'Clinical utility message testing', detail: 'What changes ordering behaviour among specialists.' },
    { name: 'ASEAN expansion linkage', detail: 'When Singapore IVD dossiers travel into ASEAN tenders.' },
  ],
  demandDrivers: {
    heading: 'Access drivers for IVD in Singapore',
    drivers: [
      { title: 'Cluster lab consolidation', detail: 'Central labs tighten platform and assay standardisation.' },
      { title: 'Precision oncology demand', detail: 'Companion and high-complexity tests raise evidence bars.' },
      { title: 'Cost-per-test scrutiny', detail: 'Procurement weighs reagent rental and throughput closely.' },
      { title: 'Point-of-care expansion', detail: 'Ward and clinic settings create parallel buyer sets.' },
      { title: 'Quality accreditation pressure', detail: 'Accreditation drives method validation timelines.' },
      { title: 'Regional HQ spotlight', detail: 'APAC teams pilot IVD stories in Singapore before ASEAN scale.' },
    ],
  },
  marketStructure: {
    heading: 'IVD access structure in Singapore',
    paragraphs: [
      'Access is multi-gated: HSA clearance, lab technical validation, clinical ordering behaviour, and budget owners. BioNixus scopes research to the gate that is currently blocking volume.',
    ],
  },
  audiences: [
    { audience: 'Lab directors & pathologists', description: 'Technical and clinical gatekeepers for assay adoption.' },
    { audience: 'Hospital procurement', description: 'Buyers scoring contracts, reagent deals, and service.' },
    { audience: 'Ordering specialists', description: 'Oncologists and other clinicians who create pull.' },
    { audience: 'IVD commercial / medical teams', description: 'Teams building Singapore and ASEAN access plans.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/clinical-diagnostics-market-research', label: 'Clinical diagnostics market research' },
    { to: '/singapore-medtech-manufacturing-market', label: 'Singapore MedTech manufacturing market' },
    { to: '/singapore-medical-devices-market-report', label: 'Singapore medical devices market report' },
  ],
  faqs: [
    {
      question: 'What does IVD market access mean in Singapore?',
      answer:
        'It means clearing regulatory, laboratory validation, clinical ordering, and procurement gates so assays generate sustained volume — not only HSA listing.',
    },
    {
      question: 'Who decides IVD adoption in Singapore hospitals?',
      answer:
        'Typically laboratory leadership plus clinical champions and procurement — with cluster standardization often binding sister hospitals.',
    },
  ],
  areaServed: ['Singapore'],
  priority: 'next',
};

const japanNeurologyDevices: SpecialtyMarketDemandContent = {
  slug: 'japan-neurology-devices-market',
  segmentLabel: 'Japan Neurology Devices',
  badge: 'Japan · Neurology Devices',
  breadcrumbLabel: 'Japan Neurology Devices Market',
  title: 'Japan Neurology Devices Market Research | BioNixus',
  description:
    'Japan neurology devices market research — neurointervention, neuromonitoring, neurosurgery capital, PMDA pathways, and hospital adoption intelligence from.',
  canonical: `${BASE}/japan-neurology-devices-market`,
  h1: 'Japan Neurology Devices Market: Clinical & Access Intelligence',
  intro: [
    'Japan’s neurology devices market concentrates in stroke intervention, neurosurgery, monitoring, and implant categories inside a high-bed, aging health system. BioNixus isolates neurology from general MedTech coverage so OEMs can brief PMDA timing, NHI category issues, and hospital KOL cascades accurately.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'Neurointerventionalist panels', detail: 'Stroke and aneurysm device choice drivers and switch barriers.' },
    { name: 'Neurosurgery capital planning', detail: 'How hospitals prioritise neuro capital budgets.' },
    { name: 'PMDA evidence expectations', detail: 'Clinical data and predicate strategies for neuro devices.' },
    { name: 'NHI category implications', detail: 'Pricing category effects on disposable versus capital mixes.' },
    { name: 'Stroke network mapping', detail: 'Which centres set protocol norms regionally.' },
    { name: 'Competitive objection libraries', detail: 'Training and complication themes that stall share gains.' },
  ],
  demandDrivers: {
    heading: 'Demand drivers',
    drivers: [
      { title: 'Aging stroke burden', detail: 'Demographic pressure lifts interventional volume.' },
      { title: 'Stroke centre designation', detail: 'Network design concentrates device utilisation.' },
      { title: 'Device lag reduction', detail: 'Faster approvals enable nearer-concurrent launches.' },
      { title: 'Training intensity', detail: 'Proctoring bandwidth gates diffusion beyond KOLs.' },
      { title: 'Hospital cost scrutiny', detail: 'High-cost disposables face sharper TCO review.' },
      { title: 'Domestic OEM presence', detail: 'Japanese manufacturers shape preference baselines.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'Volume concentrates in designated stroke and university neurosurgery centres. Distributor technical specialists and proctors are part of the commercial system BioNixus maps alongside clinical preference.',
    ],
  },
  audiences: [
    { audience: 'Neurointerventionalists & neurosurgeons', description: 'Primary clinical decision makers.' },
    { audience: 'Stroke unit / ICU leads', description: 'Protocol and pathway influencers.' },
    { audience: 'Hospital procurement', description: 'Capital and disposable contract owners.' },
    { audience: 'Biomedical engineering', description: 'Maintenance and inventory stakeholders.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/japan-general-surgical-devices-market', label: 'Japan general surgical devices market' },
    { to: '/japan-medical-devices-market-report', label: 'Japan medical devices market report' },
    { to: '/healthcare-market-research-japan', label: 'Healthcare market research Japan' },
  ],
  faqs: [
    {
      question: 'What does the Japan neurology devices market include?',
      answer:
        'Neurointervention consumables and capital, neurosurgical instruments, neuromonitoring, and related implants — researched as a distinct decision set from broad MedTech.',
    },
  ],
  areaServed: ['Japan'],
  priority: 'next',
};

const japanMedicalDisposables: SpecialtyMarketDemandContent = {
  slug: 'japan-medical-disposables-market',
  segmentLabel: 'Japan Medical Disposables',
  badge: 'Japan · Disposables',
  breadcrumbLabel: 'Japan Medical Disposables Market',
  title: 'Japan Medical Disposables Market Research | BioNixus',
  description:
    'Japan medical disposables market research — hospital consumables, infection-control products, tender dynamics, and procurement behaviour intelligence from.',
  canonical: `${BASE}/japan-medical-disposables-market`,
  h1: 'Japan Medical Disposables Market: Procurement & Adoption Intelligence',
  intro: [
    'Japan’s medical disposables market is high-volume, committee-governed, and sensitive to infection-control standards and total cost. BioNixus researches nursing, infection control, and procurement stakeholders to show which SKUs earn formulary permanency versus perpetual trial status.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'Infection-control product research', detail: 'PPE, drapes, and antiseptic category choice drivers.' },
    { name: 'Ward nursing preference studies', detail: 'Usability and workflow friction on high-turn SKUs.' },
    { name: 'Hospital tender intelligence', detail: 'How standardization and dual-source rules operate.' },
    { name: 'Private vs public account mix', detail: 'Where volume and margin actually concentrate.' },
    { name: 'Competitive switching barriers', detail: 'Training, kit design, and contract lock-ins.' },
    { name: 'GCC export linkage', detail: 'When Japanese disposable credentials travel into Gulf tenders.' },
  ],
  demandDrivers: {
    heading: 'Demand drivers',
    drivers: [
      { title: 'Infection prevention standards', detail: 'Hospital QI programmes sustain premium disposables demand.' },
      { title: 'Nursing workflow pressure', detail: 'Usability often outweighs small unit-price gaps.' },
      { title: 'Central tendering', detail: 'Group purchasing compresses net prices and raises service expectations.' },
      { title: 'Aging inpatient volumes', detail: 'Bed utilisation keeps baseline consumable demand elevated.' },
      { title: 'Domestic manufacturing', detail: 'Japanese suppliers remain default referents for many categories.' },
      { title: 'Sustainability scrutiny', detail: 'Green procurement criteria begin to appear in evaluations.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'Disposables decisions mix nursing preference, infection-control policy, and purchasing contracts. Successful research treats those lanes explicitly instead of averaging them.',
    ],
  },
  audiences: [
    { audience: 'Infection-control leads', description: 'Policy gatekeepers for many disposable categories.' },
    { audience: 'Ward nursing managers', description: 'Daily users who veto poor workflow products.' },
    { audience: 'Hospital procurement', description: 'Contract and standardization owners.' },
    { audience: 'Distributor partners', description: 'Logistics and service intermediaries.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/japan-general-surgical-devices-market', label: 'Japan general surgical devices market' },
    { to: '/japan-medical-devices-market-report', label: 'Japan medical devices market report' },
    { to: '/gcc-medical-devices-market-report', label: 'GCC medical devices market report' },
  ],
  faqs: [
    {
      question: 'What is included in Japan medical disposables research?',
      answer:
        'High-turn hospital consumables — infection-control products, procedure packs, and related single-use categories — researched through nursing, infection control, and procurement lenses.',
    },
  ],
  areaServed: ['Japan'],
  priority: 'next',
};

const japanMedtechAccessAutomation: SpecialtyMarketDemandContent = {
  slug: 'japan-medical-device-market-access',
  segmentLabel: 'Japan Medical Device Market Access',
  badge: 'Japan · Access & Automation',
  breadcrumbLabel: 'Japan Medical Device Market Access',
  title: 'Japan Medical Device Market Access & Automation | BioNixus',
  description:
    'Japan medical device market access and medical automation research — PMDA pathways, NHI listing, hospital automation adoption, and procurement.',
  canonical: `${BASE}/japan-medical-device-market-access`,
  h1: 'Japan Medical Device Market Access & Medical Automation Intelligence',
  intro: [
    'Queries for “Japan medical device market access” and “Japan medical automation market” share one commercial intent: understand the gates between PMDA clearance and paid hospital use — including automation platforms that change staffing and capital calculus. BioNixus researches HTA-adjacent stakeholders, hospital CIOs/biomed teams, and clinicians to stress-test access and automation narratives together.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'PMDA-to-NHI pathway research', detail: 'Timing, evidence, and category strategy for access.' },
    { name: 'Hospital automation readiness', detail: 'Pharmacy, lab, and OR automation buyer maps.' },
    { name: 'CIO / biomed capital scoring', detail: 'How IT and engineering evaluate automation ROI.' },
    { name: 'Workforce substitution perceptions', detail: 'Nursing and pharmacist attitudes to automation.' },
    { name: 'Competitive access benchmarking', detail: 'Analogues that recently cleared or stalled.' },
    { name: 'Service & uptime value tests', detail: 'Contract attributes that win after list price.' },
  ],
  demandDrivers: {
    heading: 'Access & automation drivers',
    drivers: [
      { title: 'Labour shortages', detail: 'Automation pitched as staffing relief faces culture and budget filters.' },
      { title: 'Device lag reforms', detail: 'Faster PMDA review raises concurrent-launch expectations.' },
      { title: 'DPC / NHI cost pressure', detail: 'Hospitals demand clear productivity or outcome proof.' },
      { title: 'Digital hospital agendas', detail: 'CIO involvement intensifies for connected devices.' },
      { title: 'Cybersecurity diligence', detail: 'Connected automation faces longer IT review cycles.' },
      { title: 'Domestic competitor strength', detail: 'Japanese automation vendors set trust baselines.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'Market access and automation purchases both require multi-stakeholder coalitions. BioNixus maps those coalitions and tests messages with each lane rather than averaging them into a single “hospital buyer” persona.',
    ],
  },
  audiences: [
    { audience: 'Hospital CIO / IT security', description: 'Connected-device and automation gatekeepers.' },
    { audience: 'Biomedical engineering', description: 'Uptime, integration, and maintenance owners.' },
    { audience: 'Clinical department heads', description: 'Productivity and safety claimants.' },
    { audience: 'Procurement / finance', description: 'Capital committee scorers.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/japan-medical-devices-market-report', label: 'Japan medical devices market report' },
    { to: '/japan-general-surgical-devices-market', label: 'Japan general surgical devices market' },
    { to: '/healthcare-bioconvergence-market', label: 'Healthcare bioconvergence market' },
  ],
  faqs: [
    {
      question: 'What is Japan medical device market access research?',
      answer:
        'Primary research that maps the practical gates from PMDA authorization to hospital payment and adoption — including committee evidence needs and automation-specific IT/workflow barriers.',
    },
  ],
  areaServed: ['Japan'],
  priority: 'next',
};

const italyClinicalTrials: SpecialtyMarketDemandContent = {
  slug: 'italy-clinical-trials-market',
  segmentLabel: 'Italy Clinical Trials Market',
  badge: 'Italy · Clinical Trials',
  breadcrumbLabel: 'Italy Clinical Trials Market',
  title: 'Italy Clinical Trials Market Research | BioNixus',
  description:
    'Italy clinical trials market research — site feasibility, ethics timelines, investigator networks, AIFA-aware context, and sponsor decision intelligence.',
  canonical: `${BASE}/italy-clinical-trials-market`,
  h1: 'Italy Clinical Trials Market: Site, Feasibility & Sponsor Intelligence',
  intro: [
    'Italy remains a major EU clinical-trial destination with dense university hospitals and specialty networks — but ethics timelines, site activation friction, and competitive enrolment determine real attractiveness. BioNixus researches investigators, site staff, and sponsor outsourcing stakeholders to support country selection and rescue decisions.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'Site feasibility & enrolment realism', detail: 'Indication-level speed and competition for patients.' },
    { name: 'Ethics / start-up intelligence', detail: 'Timeline and documentation friction by region and site type.' },
    { name: 'Investigator network mapping', detail: 'Which centres actually enrol versus claim capacity.' },
    { name: 'CRO / FSP perception research', detail: 'Sponsor and site views of delivery models in Italy.' },
    { name: 'Therapeutic area concentration', detail: 'Oncology, rare disease, and cardiology site strength.' },
    { name: 'EU CTR operational implications', detail: 'How CTR implementation is felt by sites and sponsors.' },
  ],
  demandDrivers: {
    heading: 'Demand drivers',
    drivers: [
      { title: 'EU CTR harmonisation', detail: 'Process changes alter relative attractiveness versus EU peers.' },
      { title: 'Oncology trial density', detail: 'Competition for patients forces sharper site selection.' },
      { title: 'Rare-disease expertise', detail: 'Specialty centres become capacity bottlenecks.' },
      { title: 'Sponsor cost pressure', detail: 'Feasibility realism valued over optimistic enrolments.' },
      { title: 'Startup timeline scrutiny', detail: 'Activation lag decides country inclusion.' },
      { title: 'Site staff bandwidth', detail: 'CRC capacity increasingly gates protocol complexity.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'Italy’s trial market is hospital-led with regional variation in ethics and contracting maturity. BioNixus scopes feasibility to the indication and phase, not national averages.',
    ],
  },
  audiences: [
    { audience: 'Principal investigators', description: 'Enrolment and scientific gatekeepers.' },
    { audience: 'Site management / CRCs', description: 'Operational capacity and friction informants.' },
    { audience: 'Sponsor clinical operations', description: 'Country-selection decision owners.' },
    { audience: 'CRO / FSP leaders', description: 'Delivery-model competitors and partners.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/gcc-clinical-trials-market', label: 'GCC clinical trials market' },
    { to: '/healthcare-market-research-italy', label: 'Healthcare market research Italy' },
    { to: '/pharmaceutical-market-research-italy', label: 'Pharmaceutical market research Italy' },
    { to: '/italy-medical-devices-market-report', label: 'Italy MedTech market research' },
  ],
  faqs: [
    {
      question: 'Why run clinical trials market research in Italy?',
      answer:
        'To validate site speed, enrolment realism, and startup friction before committing country budgets — especially in competitive oncology and rare-disease indications.',
    },
  ],
  areaServed: ['Italy'],
  priority: 'next',
};

const mekInhibitors: SpecialtyMarketDemandContent = {
  slug: 'mek-inhibitors-market',
  segmentLabel: 'MEK Inhibitors Market Access',
  badge: 'Global / GCC · Oncology Access',
  breadcrumbLabel: 'MEK Inhibitors Market Access',
  title: 'MEK Inhibitors Market Access Research | BioNixus',
  description:
    'MEK inhibitors market access research — oncology prescribing, biomarker testing, payer evidence needs, and GCC tender dynamics from BioNixus.',
  canonical: `${BASE}/mek-inhibitors-market`,
  h1: 'MEK Inhibitors Market Access: Oncology Evidence & Commercial Intelligence',
  intro: [
    'MEK inhibitor access decisions turn on biomarker pathway readiness, line-of-therapy sequencing, and payer evidence — not brand awareness alone. BioNixus runs oncologist, molecular-pathology, and access interviews to show where MEK classes win protocol space and where testing or funding gates stall uptake, with GCC modules when tender listing is on the path.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'Oncologist treatment sequencing', detail: 'Where MEK sits versus competing targeted options.' },
    { name: 'Biomarker testing readiness', detail: 'Molecular pathology capacity and turnaround barriers.' },
    { name: 'Payer / HTA evidence expectations', detail: 'What dossiers must prove for funding.' },
    { name: 'GCC tender & formulary modules', detail: 'NUPCO and hospital listing dynamics for high-cost oncology.' },
    { name: 'Patient-support & adherence', detail: 'Programme attributes that change real-world persistence.' },
    { name: 'Competitive message testing', detail: 'Safety, efficacy, and convenience themes that move share.' },
  ],
  demandDrivers: {
    heading: 'Access drivers',
    drivers: [
      { title: 'Precision-oncology expansion', detail: 'More tested patients create eligible pools — when labs keep up.' },
      { title: 'Combination regimens', detail: 'Partner drug access can gate MEK utilisation.' },
      { title: 'High-cost scrutiny', detail: 'Payers demand clearer sequencing rationale.' },
      { title: 'GCC framework awards', detail: 'Listing without pull-through leaves volume stranded.' },
      { title: 'Indication breadth', detail: 'Label expansions change competitive sets quickly.' },
      { title: 'RWE expectations', detail: 'Local evidence increasingly requested at committee.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'MEK access is oncology-network and testing-dependent. BioNixus designs modules by indication cluster and geography rather than treating “MEK market” as one homogeneous category.',
    ],
  },
  audiences: [
    { audience: 'Medical oncologists', description: 'Prescribing decision owners.' },
    { audience: 'Molecular pathologists', description: 'Testing pathway gatekeepers.' },
    { audience: 'Hospital formulary / payers', description: 'Funding and listing stakeholders.' },
    { audience: 'Medical affairs / access teams', description: 'Evidence and messaging owners.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/febrile-neutropenia-market', label: 'Febrile neutropenia market' },
    { to: '/healthcare-market-research/therapy/oncology', label: 'Oncology market research' },
    { to: '/market-reports/gcc-oncology-market-report', label: 'GCC oncology market report' },
    { to: '/real-world-evidence', label: 'Real world evidence' },
  ],
  faqs: [
    {
      question: 'What is MEK inhibitors market access research?',
      answer:
        'Primary research with oncology, pathology, and funding stakeholders that maps the practical barriers between regulatory approval and sustained utilisation for MEK inhibitor classes.',
    },
  ],
  priority: 'next',
};

const febrileNeutropenia: SpecialtyMarketDemandContent = {
  slug: 'febrile-neutropenia-market',
  segmentLabel: 'Febrile Neutropenia Market',
  badge: 'Global / GCC · Supportive Care',
  breadcrumbLabel: 'Febrile Neutropenia Market',
  title: 'Febrile Neutropenia Market Research | BioNixus',
  description:
    'Febrile neutropenia market research — G-CSF supportive care, hospital protocols, oncology pharmacy practice, and GCC tender intelligence from BioNixus.',
  canonical: `${BASE}/febrile-neutropenia-market`,
  h1: 'Febrile Neutropenia Market: Supportive-Care & Protocol Intelligence',
  intro: [
    'The febrile neutropenia market is driven by oncology regimen intensity, hospital prophylaxis protocols, and biosimilar G-CSF competition more than consumer awareness. BioNixus researches oncologists, oncology pharmacists, and tender stakeholders to forecast switching and protocol stickiness — including Gulf hospital settings where supportive-care injectables move through frameworks.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'Prophylaxis protocol research', detail: 'When hospitals choose primary vs secondary prophylaxis.' },
    { name: 'G-CSF brand / biosimilar switching', detail: 'Pharmacist and oncologist confidence drivers.' },
    { name: 'Inpatient pathway mapping', detail: 'Admission and antibiotic pathway implications for brands.' },
    { name: 'GCC tender modules', detail: 'Framework dynamics for supportive-care injectables.' },
    { name: 'Nursing administration friction', detail: 'Device and schedule attributes that affect preference.' },
    { name: 'Competitive message tests', detail: 'Safety, convenience, and supply themes that move share.' },
  ],
  demandDrivers: {
    heading: 'Demand drivers',
    drivers: [
      { title: 'Myelosuppressive regimens', detail: 'Oncology protocol mix sets the addressable prophylaxis pool.' },
      { title: 'Biosimilar pressure', detail: 'Hospital pharmacies accelerate switches after tender change.' },
      { title: 'Length-of-stay objectives', detail: 'Hospitals value regimens that reduce FN admissions.' },
      { title: 'Supply reliability', detail: 'Shortage history influences dual-source policies.' },
      { title: 'Day-clinic expansion', detail: 'Outpatient oncology changes administration preferences.' },
      { title: 'Guideline updates', detail: 'Society guidance shifts prophylaxis thresholds.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'FN markets are protocol- and tender-shaped. BioNixus isolates prophylaxis choice, secondary treatment, and tender award as distinct research questions.',
    ],
  },
  audiences: [
    { audience: 'Medical oncologists', description: 'Protocol decision owners.' },
    { audience: 'Oncology pharmacists', description: 'Substitution and tender influencers.' },
    { audience: 'Hospital infectious disease', description: 'Admission pathway stakeholders.' },
    { audience: 'Procurement / tenders', description: 'Framework and award decision makers.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/mek-inhibitors-market', label: 'MEK inhibitors market access' },
    { to: '/gcc-generic-injectables-market', label: 'GCC generic injectables market' },
    { to: '/healthcare-market-research/therapy/oncology', label: 'Oncology market research' },
    { to: '/market-reports/gcc-oncology-market-report', label: 'GCC oncology market report' },
  ],
  faqs: [
    {
      question: 'What drives the febrile neutropenia market?',
      answer:
        'Oncology regimen myelosuppression, prophylaxis guidelines, hospital pharmacy substitution, and tender awards for G-CSF and related supportive care — researched by BioNixus through clinical and procurement stakeholders.',
    },
  ],
  priority: 'next',
};

/* ------------------------------------------------------------------ */
/* LATER                                                              */
/* ------------------------------------------------------------------ */

const italyPortableDiagnostics: SpecialtyMarketDemandContent = {
  slug: 'italy-portable-diagnostic-devices-market',
  segmentLabel: 'Italy Portable Diagnostic Devices',
  badge: 'Italy · Portable Diagnostics',
  breadcrumbLabel: 'Italy Portable Diagnostic Devices Market',
  title: 'Italy Portable Diagnostic Devices Market Research | BioNixus',
  description:
    'Italy portable diagnostic devices market research — POCT adoption, hospital and community laboratory pathways, AIFA/notified-body context, and procurement.',
  canonical: `${BASE}/italy-portable-diagnostic-devices-market`,
  h1: 'Italy Portable Diagnostic Devices Market: POCT & Adoption Intelligence',
  intro: [
    'Italy’s portable diagnostic devices market is shaped by hospital POCT programmes, community laboratory networks, and regional procurement rules more than retail gadget demand. BioNixus researches laboratory directors, emergency and ward clinicians, and ASL/hospital buyers to show which handheld and near-patient platforms clear volume — and which remain pilots.',
    'Queries such as “Italy microservices healthcare market” and “Italy portable diagnostic devices market” often reflect the same buyer anxiety: who funds POCT inside fragmented regional health systems, and what integration evidence survives ASL tender committees. We separate acute ED/ward POCT, ambulatory cardiometabolic monitoring, and community-lab decentralisation so IVD vendors do not conflate incompatible adoption curves.',
    'Central laboratory consolidation across Italian regions creates tension with decentralised POCT: lab directors defend send-out economics while ED physicians demand faster panels. BioNixus maps where that tension resolves toward expansion versus rollback — the difference between a sustainable installed base and a pilot that never renews.',
    'EU IVDR post-market surveillance and method-validation requirements lengthen evaluation cycles. Italian hospital committees now treat connectivity, QC burden, and reagent-contract economics as mandatory scoring criteria alongside clinical accuracy claims.',
    'BioNixus clients typically commission Italy POCT research before ASL tender seasons or immediately after pilot completion — the two windows where lab-director and procurement interviews change vendor outcomes.',
    'We publish pathway-specific intelligence — not syndicated market-size guesses — so IVD commercial teams can defend tender submissions and renewal conversations with credible primary evidence.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'POCT programme mapping', detail: 'Where Italy hospitals authorize, train, and govern near-patient testing.' },
    { name: 'Lab director adoption research', detail: 'Quality, connectivity, and reagent-contract barriers to scale.' },
    { name: 'Clinical pathway interviews', detail: 'ED, ward, and ambulatory use cases that create real pull.' },
    { name: 'Regional procurement signals', detail: 'How regional tenders and hospital groups score portable platforms.' },
    { name: 'Competitive installed-base research', detail: 'Switch costs versus benchtop and central-lab alternatives.' },
    { name: 'EU MDR / IVDR evidence needs', detail: 'Documentation and PMS expectations that affect Italy timelines.' },
  ],
  demandDrivers: {
    heading: 'Demand drivers',
    drivers: [
      { title: 'ED and ward turnaround pressure', detail: 'Faster decisions favour near-patient panels when quality holds.' },
      { title: 'Workforce constraints', detail: 'Staffing shortages raise interest in compact workflows.' },
      { title: 'Regional lab consolidation', detail: 'Central labs reassess which tests stay decentralised.' },
      { title: 'Chronic ambulatory monitoring', detail: 'Cardiometabolic and respiratory use cases expand beyond acute care.' },
      { title: 'Reagent rental economics', detail: 'Total cost and throughput decide renewals more than list price.' },
      { title: 'Connectivity expectations', detail: 'LIS/HIS integration is now a table-stakes evaluation criterion.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'Portable diagnostics in Italy sit between laboratory governance and clinical urgency. BioNixus separates acute POCT, ambulatory programmes, and community pathways so manufacturers do not average incompatible buyer sets.',
      'Regional ASL procurement and university-hospital reference centres create a two-speed market — innovation pilots in tertiary hubs versus price-sensitive community adoption. Reagent-rental economics and LIS connectivity are now table-stakes evaluation criteria in both channels.',
      'BioNixus programmes typically produce three outputs: a pathway map showing where POCT expands versus send-out testing, an ASL tender-scoring guide with integration and QC evidence requirements, and a renewal-risk assessment based on lab-director and nursing interviews.',
      'Manufacturers should not extrapolate Italy opportunity from retail gadget trends or syndicated IVD totals — hospital governance and IVDR validation cycles determine real installed-base growth.',
    ],
  },
  signalGrid: {
    heading: 'Regional signals',
    items: [
      { label: 'Lombardy / Emilia-Romagna', signal: 'High POCT density; strict lab-director governance on method validation.' },
      { label: 'Lazio / Campania', signal: 'ED turnaround pressure drives near-patient panels when quality holds.' },
      { label: 'Piedmont / Tuscany', signal: 'Regional tenders increasingly specify interoperability clauses.' },
      { label: 'Southern ASLs', signal: 'Workforce constraints raise interest in compact workflows; capex cycles longer.' },
    ],
  },
  audiences: [
    { audience: 'Laboratory directors', description: 'Quality and method-validation gatekeepers.' },
    { audience: 'ED / ward clinical leads', description: 'Pathway owners who create ordering pull.' },
    { audience: 'Hospital / ASL procurement', description: 'Contract and tender decision makers.' },
    { audience: 'IT / connectivity owners', description: 'Integration and cybersecurity reviewers.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/italy-clinical-trials-market', label: 'Italy clinical trials market' },
    { to: '/italy-medical-device-connectivity-market', label: 'Italy medical device connectivity market' },
    { to: '/italy-medical-devices-market-report', label: 'Italy MedTech market research' },
    { to: '/clinical-diagnostics-market-research', label: 'Clinical diagnostics market research' },
    { to: '/pharmaceutical-market-research-italy', label: 'Pharmaceutical market research Italy' },
    { to: '/healthcare-market-research-italy', label: 'Healthcare market research Italy' },
  ],
  faqs: [
    {
      question: 'What is the Italy portable diagnostic devices market?',
      answer:
        'Near-patient and handheld diagnostic platforms used in hospitals, ambulatory settings, and selected community pathways — researched through laboratory, clinical, and procurement stakeholders rather than consumer gadget panels.',
    },
    {
      question: 'How do Italian hospital POCT programmes differ from retail diagnostics?',
      answer:
        'Hospital POCT requires laboratory-director method validation, quality control, and LIS integration — governed separately from retail self-test devices. BioNixus researches the hospital governance chain, not consumer adoption panels.',
    },
    {
      question: 'What role do ASL regional tenders play in portable diagnostics?',
      answer:
        'Regional health authorities (ASL) run tenders that score interoperability, reagent economics, and service support alongside list price. Winning an ASL framework does not guarantee ward-level pull-through — BioNixus measures clinical ordering behaviour post-award.',
    },
    {
      question: 'How does EU IVDR affect Italy POCT timelines?',
      answer:
        'IVDR documentation and post-market surveillance expectations extend approval and renewal cycles. Italian lab directors scrutinise performance data and connectivity evidence before authorising new near-patient menus.',
    },
    {
      question: 'Can BioNixus research ED versus ward POCT use cases separately?',
      answer:
        'Yes — ED turnaround drivers differ from ward monitoring and ambulatory cardiometabolic programmes. We scope quotas by pathway so manufacturers do not average incompatible clinical urgency profiles.',
    },
    {
      question: 'How large is the Italy portable diagnostics opportunity versus central lab testing?',
      answer:
        'Italy maintains one of Europe’s densest central-laboratory networks, yet ED and ward POCT continues to expand where turnaround time saves admission decisions. The portable opportunity is pathway-specific — not a wholesale replacement of benchtop menus. BioNixus sizes decision cells with laboratory directors rather than extrapolating from gadget retail trends.',
    },
    {
      question: 'Which Italian stakeholders veto POCT scale-up after pilot success?',
      answer:
        'Laboratory directors control method validation and quality budgets; clinical engineering owns connectivity; ASL procurement scores tender economics; ward nurses determine daily workflow friction. A successful pilot in one university hospital does not propagate until each coalition member’s objections are addressed — BioNixus maps veto and acceleration power explicitly.',
    },
    {
      question: 'How do reagent rental contracts shape portable diagnostics renewals in Italy?',
      answer:
        'Most hospital POCT platforms run on reagent rental or minimum-volume contracts where throughput and menu breadth matter more than instrument list price. Renewal decisions hinge on LIS integration stability, QC burden, and comparative cost versus send-out testing. BioNixus researches renewal drivers with lab finance and operations stakeholders.',
    },
    {
      question: 'What competitive dynamics affect portable diagnostics in Italian EDs?',
      answer:
        'Multinational IVD incumbents defend installed base with connectivity bundles and service networks; challengers win on menu expansion and turnaround claims when lab directors trust validation data. BioNixus builds objection libraries from ED physicians and lab directors who experience daily ordering friction — not from syndicated share charts alone.',
    },
    {
      question: 'How should IVD vendors sequence Italy POCT research before tender season?',
      answer:
        'Run lab-director and ED physician modules before ASL framework drafts circulate — objection libraries and connectivity evidence packs need to be ready when specifications freeze. Post-award pull-through research confirms whether tender wins convert to ward ordering or remain shelfware.',
    },
    {
      question: 'Does BioNixus cover ambulatory cardiometabolic monitoring in Italy?',
      answer:
        'Yes — ambulatory pathways (cardiometabolic, respiratory, anticoagulation monitoring) follow different buyer sets from acute POCT. We scope community-lab and specialist-clinic quotas separately from hospital ED modules.',
    },
    {
      question: 'How do Italian university hospitals influence community POCT adoption?',
      answer:
        'University reference centres validate methods and train community lab directors — creating a KOL cascade similar to surgical device markets. BioNixus maps which reference sites actually drive regional ASL decisions versus which remain academic pilots with limited pull-through.',
    },
    {
      question: 'What connectivity standards do Italian hospitals require for POCT?',
      answer:
        'LIS bidirectional interfaces, QC data capture, operator authentication, and cybersecurity review are now standard tender clauses. Vendors without proven Italian hospital integrations face long IT approval cycles even when clinical accuracy is accepted.',
    },
    {
      question: 'How long do Italy POCT pilot-to-scale cycles typically run?',
      answer:
        'Pilots often run 6–12 months before ASL or hospital committees authorise network expansion — longer when IVDR documentation or LIS integration slips. BioNixus tracks pilot exit criteria with lab directors so vendors know whether scale-up is realistic before investing in tender defence.',
    },
    {
      question: 'Does BioNixus research POCT for infectious-disease panels in Italy?',
      answer:
        'Yes — ED and ward infectious-disease POCT follows distinct pathway and validation rules from cardiometabolic monitoring. We scope menu-specific modules when respiratory, sepsis, or combined panels are the commercial question.',
    },
    {
      question: 'How do central-lab send-out economics interact with POCT expansion in Italy?',
      answer:
        'Laboratory directors weigh send-out cost and turnaround against POCT QC burden and connectivity investment. BioNixus models that trade-off with finance and operations stakeholders — the decision that determines whether pilots renew or revert to central testing.',
    },
    {
      question: 'What sample sizes suffice for Italy POCT qualitative programmes?',
      answer:
        'Qualitative saturation targets role, region, and pathway — typically 12–20 lab-director and clinician interviews per scoped module before diminishing returns. Quant validation waves follow when segment hypotheses must be stress-tested across multiple ASL regions.',
    },
    {
      question: 'Can Italy POCT evidence support broader EU5 tender strategies?',
      answer:
        'Italian lab-director validation data can inform EU5 dossiers when connectivity and QC protocols translate — but ASL-specific tender scoring remains local. BioNixus flags which evidence travels versus which must be regenerated per country.',
    },
  ],
  areaServed: ['Italy'],
  geoAnswerBlock: {
    question: 'What is the Italy portable diagnostic devices market?',
    answer:
      'Italy’s portable diagnostic devices market is hospital POCT, ambulatory monitoring, and community-lab decentralisation — governed by laboratory directors, ASL procurement, and EU IVDR evidence requirements. BioNixus researches pathologists, ED physicians, and biomedical engineering to show which near-patient platforms clear volume versus remain pilots.',
    points: [
      {
        title: 'Hospital POCT governance',
        description:
          'Lab directors control method validation, QC budgets, and LIS integration — distinct from retail self-test adoption panels.',
      },
      {
        title: 'ED & ward turnaround',
        description:
          'Acute pathways favour near-patient panels when quality and connectivity survive committee scrutiny.',
      },
      {
        title: 'ASL regional tenders',
        description:
          'Regional health authorities score interoperability, reagent economics, and service support alongside list price.',
      },
      {
        title: 'IVDR & renewal cycles',
        description:
          'Post-market surveillance and validation burden shape renewal decisions more than initial pilot enthusiasm.',
      },
    ],
    summary:
      'Request an Italy portable diagnostics research briefing through BioNixus contact — scoped to ED, ward, or ambulatory pathways.',
  },
  methodologySection: {
    heading: 'How BioNixus researches Italy portable diagnostics',
    paragraphs: [
      'Programmes open with pathway scoping — acute ED/ward POCT, ambulatory cardiometabolic monitoring, or community-lab decentralisation — because buyer sets and validation rules differ materially across those cells.',
      'Recruitment prioritises laboratory directors, ED and ward clinical leads, ASL procurement reviewers, and biomedical engineering connectivity owners. Quotas reflect region and institution tier so national narratives do not hide ASL-specific veto players.',
      'Fieldwork tests method-validation burden, LIS integration realism, reagent-contract economics, and QC workflow fit — the gates that determine renewal more often than initial pilot enthusiasm. Competitive modules capture incumbent defence themes from lab directors who manage daily ordering friction.',
      'Outputs include pathway maps, ASL tender-scoring guides, renewal-risk assessments, and objection libraries suitable for global IVD portfolio committees. Appendix layers document quota logs and instrument versioning for governance teams.',
      'Italy modules often pair with clinical diagnostics market research and pharmaceutical market research Italy when IVD vendors span hospital and ambulatory portfolios across the same ASL regions.',
      'Contact BioNixus for a scoped Italy portable diagnostics proposal — pathway-specific modules for ED, ward, or ambulatory programmes with governance-ready appendix layers and ASL-aligned tender timing.',
    ],
  },
  priority: 'next',
};

const italyDeviceConnectivity: SpecialtyMarketDemandContent = {
  slug: 'italy-medical-device-connectivity-market',
  segmentLabel: 'Italy Medical Device Connectivity',
  badge: 'Italy · Digital Health / Connectivity',
  breadcrumbLabel: 'Italy Medical Device Connectivity Market',
  title: 'Italy Medical Device Connectivity & Digital Health | BioNixus',
  description:
    'Italy medical device connectivity and digital health market research — HIS/LIS integration, hospital microservices architectures, cybersecurity diligence.',
  canonical: `${BASE}/italy-medical-device-connectivity-market`,
  h1: 'Italy Medical Device Connectivity & Digital Health Market Intelligence',
  intro: [
    'Queries for “Italy medical device connectivity market” and “Italy microservices healthcare market” point to the same commercial gap: who funds, integrates, and greets connected devices inside Italian hospital IT stacks. BioNixus interviews CIOs, clinical engineering, cybersecurity, and department heads to test whether connectivity claims survive procurement and go-live.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'HIS / LIS / PACS integration research', detail: 'What interfaces and middleware hospitals actually require.' },
    { name: 'Microservices & architecture diligence', detail: 'How IT teams evaluate modular vs monolithic vendor stacks.' },
    { name: 'Cybersecurity and GDPR review gates', detail: 'Evidence packs that unblock connected-device tenders.' },
    { name: 'Clinical engineering workflows', detail: 'Uptime, patching, and fleet-management expectations.' },
    { name: 'Department buying coalitions', detail: 'Who sponsors connectivity spend beyond the IT budget.' },
    { name: 'Competitive objection libraries', detail: 'Why incumbents retain share after RFP shortlists.' },
  ],
  demandDrivers: {
    heading: 'Demand drivers',
    drivers: [
      { title: 'Hospital digitalisation agendas', detail: 'National and regional digital health programmes raise integration expectations.' },
      { title: 'Cybersecurity scrutiny', detail: 'Connected fleets face longer IT approval cycles.' },
      { title: 'Staffing productivity pressure', detail: 'Automation and remote monitoring need clean data plumbing.' },
      { title: 'Vendor consolidation', detail: 'Hospitals prefer fewer platforms with proven interfaces.' },
      { title: 'MDR PMS / data obligations', detail: 'Post-market surveillance pushes better device data capture.' },
      { title: 'Regional tender complexity', detail: 'Specifications increasingly include interoperability clauses.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'Connectivity purchases are coalition buys across IT, clinical engineering, and clinical departments. BioNixus maps those coalitions and tests microservices/interoperability claims with the people who can veto go-live.',
    ],
  },
  audiences: [
    { audience: 'Hospital CIO / IT architecture', description: 'Integration and platform decision owners.' },
    { audience: 'Cybersecurity leads', description: 'Gatekeepers for connected-device risk acceptance.' },
    { audience: 'Clinical engineering', description: 'Fleet, uptime, and maintenance stakeholders.' },
    { audience: 'Clinical department heads', description: 'Sponsors who create budget and workflow pull.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/italy-portable-diagnostic-devices-market', label: 'Italy portable diagnostic devices market' },
    { to: '/italy-clinical-trials-market', label: 'Italy clinical trials market' },
    { to: '/italy-medical-devices-market-report', label: 'Italy MedTech market research' },
    { to: '/healthcare-bioconvergence-market', label: 'Healthcare bioconvergence market' },
    { to: '/healthcare-market-research-italy', label: 'Healthcare market research Italy' },
    { to: '/japan-medical-device-market-access', label: 'Japan medical device market access' },
  ],
  faqs: [
    {
      question: 'What does Italy medical device connectivity research cover?',
      answer:
        'Primary research on how Italian hospitals evaluate device-to-HIS/LIS integration, microservices architectures, cybersecurity, and clinical go-live — the gates that decide whether connected MedTech actually deploys.',
    },
  ],
  areaServed: ['Italy'],
  priority: 'later',
};

const italyOncologyAntiInfectiveAccess: SpecialtyMarketDemandContent = {
  slug: 'italy-oncology-antiinfective-market-access',
  segmentLabel: 'Italy Oncology & Anti-infective Access',
  badge: 'Italy · Oncology / Anti-infective Access',
  breadcrumbLabel: 'Italy Oncology & Anti-infective Market Access',
  title: 'Italy Oncology & Anti-infective Market Access Research | BioNixus',
  description:
    'Italy oncology and anti-infective market access research — Keytruda-class IO analogues, daptomycin-class hospital antibiotics, AIFA/regional pathways, and.',
  canonical: `${BASE}/italy-oncology-antiinfective-market-access`,
  h1: 'Italy Oncology & Anti-infective Market Access: AIFA, Hospital & Regional Intelligence',
  intro: [
    'Search interest in “Italy Keytruda market” and “Italy daptomycin market” is access intent: how IO and high-value hospital anti-infectives clear AIFA, regional, and hospital formulary gates. BioNixus runs oncologist, infectious-disease, hospital pharmacy, and access interviews so commercial teams see protocol share and funding friction separately — not as a single national average.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'IO / Keytruda-class access mapping', detail: 'Indication sequencing, biomarker testing, and regional funding friction.' },
    { name: 'Hospital antibiotic formulary research', detail: 'Daptomycin-class stewardship, substitution, and tender dynamics.' },
    { name: 'AIFA and regional pathway interviews', detail: 'What evidence and negotiation realities shape listing timelines.' },
    { name: 'Hospital P&T behaviour', detail: 'How pharmacy and clinical committees convert listing into protocol use.' },
    { name: 'Competitive analogue libraries', detail: 'Messaging and objection themes in crowded IO and anti-infective sets.' },
    { name: 'RWE expectations', detail: 'Local evidence requests that delay or accelerate uptake.' },
  ],
  demandDrivers: {
    heading: 'Access drivers',
    drivers: [
      { title: 'Indication expansion waves', detail: 'New IO labels reopen sequencing debates hospital by hospital.' },
      { title: 'Biomarker capacity', detail: 'Testing turnaround gates eligible patient pools.' },
      { title: 'Antimicrobial stewardship', detail: 'ID and pharmacy policy shape anti-infective choice beyond price.' },
      { title: 'Regional budget variation', detail: 'Italy’s regionalisation creates uneven access timing.' },
      { title: 'Tender and net-price pressure', detail: 'Hospital purchasing compresses margins after list access.' },
      { title: 'Combination regimens', detail: 'Partner-drug access can stall or unlock protocol share.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'Oncology IO and hospital anti-infectives share high-cost scrutiny but different clinical governors — oncology networks versus stewardship committees. BioNixus scopes modules by class and decides whether national, regional, or account-level cells are needed.',
    ],
  },
  audiences: [
    { audience: 'Medical oncologists', description: 'IO sequencing and protocol decision owners.' },
    { audience: 'Infectious disease & stewardship leads', description: 'Anti-infective policy gatekeepers.' },
    { audience: 'Hospital pharmacists', description: 'Formulary and tender influencers.' },
    { audience: 'Access / HEOR teams', description: 'AIFA and regional dossier owners.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/mek-inhibitors-market', label: 'MEK inhibitors market access' },
    { to: '/doxorubicin-market', label: 'Doxorubicin market access' },
    { to: '/febrile-neutropenia-market', label: 'Febrile neutropenia market' },
    { to: '/pharmaceutical-market-research-italy', label: 'Pharmaceutical market research Italy' },
    { to: '/healthcare-market-research/therapy/oncology', label: 'Oncology market research' },
    { to: '/italy-clinical-trials-market', label: 'Italy clinical trials market' },
  ],
  faqs: [
    {
      question: 'How does BioNixus research Italy Keytruda-class or daptomycin-class markets?',
      answer:
        'We run primary interviews with the clinical and formulary stakeholders who control protocol and funding decisions for the relevant class — IO oncology networks for checkpoint analogues; infectious-disease and hospital pharmacy for high-value anti-infectives — mapped to AIFA and regional access context.',
    },
  ],
  areaServed: ['Italy'],
  priority: 'later',
};

const gccFspMarket: SpecialtyMarketDemandContent = {
  slug: 'gcc-functional-service-providers-market',
  segmentLabel: 'GCC Functional Service Providers',
  badge: 'GCC · Clinical Development / FSP',
  breadcrumbLabel: 'GCC FSP Market',
  title: 'GCC Functional Service Providers (FSP) Market Research | BioNixus',
  description:
    'GCC functional service providers market research — FSP vs full-service outsourcing, clinical operations capacity, sponsor buyer criteria, and Gulf trial.',
  canonical: `${BASE}/gcc-functional-service-providers-market`,
  h1: 'GCC Functional Service Providers (FSP) Market: Sponsor & Delivery Intelligence',
  intro: [
    'The GCC functional service providers market sits at the intersection of rising Gulf clinical-trial ambition and sponsor preference for modular FSP models over full-service CROs. BioNixus researches sponsor clinical-operations leaders, site networks, and in-region delivery partners to show which FSP capabilities win Gulf assignments — monitoring, data management, medical writing, pharmacovigilance — and where full-service still dominates.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'Sponsor outsourcing model research', detail: 'When Gulf programmes choose FSP vs full-service vs hybrid.' },
    { name: 'Capability-by-function mapping', detail: 'Monitoring, DM, medical writing, PV, and biostat preferences.' },
    { name: 'In-region delivery diligence', detail: 'Arabic capability, hospital access, and travel logistics as win themes.' },
    { name: 'Site & investigator experience research', detail: 'How FSP CRA models feel to Gulf sites versus legacy CROs.' },
    { name: 'Pricing and governance interviews', detail: 'What KPIs and governance sponsors demand from FSP partners.' },
    { name: 'Competitive landscape briefs', detail: 'Global FSP brands vs regional specialists in Saudi Arabia and UAE.' },
  ],
  demandDrivers: {
    heading: 'Demand drivers',
    drivers: [
      { title: 'Gulf trial volume growth', detail: 'More Phase II–IV and RWE programmes need flexible resourcing.' },
      { title: 'Sponsor cost pressure', detail: 'FSP models promise utilisation control versus full-service lock-in.' },
      { title: 'Localisation expectations', detail: 'Saudi and UAE programmes favour partners with in-market presence.' },
      { title: 'Startup timeline scrutiny', detail: 'Site activation speed is a decisive selection criterion.' },
      { title: 'Therapeutic specialisation', detail: 'Oncology and rare-disease depth beats generic capacity claims.' },
      { title: 'Quality / inspection readiness', detail: 'GCP inspection risk pushes sponsors toward proven oversight models.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'FSP buying in the GCC is rarely a single RFP for “the region.” Sponsors often lock global FSP frameworks then stress-test Middle East delivery cells. BioNixus scopes research to the function and geography under evaluation.',
    ],
  },
  signalGrid: {
    heading: 'Country signals',
    items: [
      { label: 'Saudi Arabia', signal: 'Largest trial and RWE ambition; localisation and SFDA context matter in partner choice.' },
      { label: 'United Arab Emirates', signal: 'Hub for regional PM and monitoring models with strong private hospital sites.' },
      { label: 'Qatar / Kuwait / Oman / Bahrain', signal: 'Smaller but strategically used cells — capacity realism is the diligence issue.' },
      { label: 'Egypt adjacency', signal: 'Often bundled into MENA FSP conversations for enrolment scale.' },
    ],
  },
  audiences: [
    { audience: 'Sponsor clinical operations', description: 'Outsourcing-model and vendor decision owners.' },
    { audience: 'FSP / CRO commercial leaders', description: 'Competitors and partners seeking Gulf win themes.' },
    { audience: 'Site / SMO leadership', description: 'Stakeholders who experience delivery quality day to day.' },
    { audience: 'Medical / PV oversight', description: 'Quality and compliance governors of modular models.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/gcc-clinical-trials-market', label: 'GCC clinical trials market' },
    { to: '/mea-clinical-trial-imaging-market', label: 'MEA clinical trial imaging market' },
    { to: '/healthcare-market-research', label: 'Healthcare market research hub' },
    { to: '/gcc-market-access-guide', label: 'GCC pharmaceutical market access guide' },
    { to: '/italy-clinical-trials-market', label: 'Italy clinical trials market' },
    { to: '/real-world-evidence', label: 'Real world evidence' },
  ],
  faqs: [
    {
      question: 'What is the GCC functional service providers market?',
      answer:
        'The market for modular clinical-development services (monitoring, data management, medical writing, PV, and related functions) sold into Gulf-sponsored or Gulf-executed programmes — researched through sponsor, site, and delivery-partner stakeholders.',
    },
  ],
  areaServed: ['Saudi Arabia', 'United Arab Emirates', 'Kuwait', 'Qatar', 'Oman', 'Bahrain'],
  priority: 'later',
};

const gccMedicationManagement: SpecialtyMarketDemandContent = {
  slug: 'gcc-medication-management-market',
  segmentLabel: 'GCC Medication Management',
  badge: 'GCC · Medication Management',
  breadcrumbLabel: 'GCC Medication Management Market',
  title: 'GCC Medication Management Market Research | BioNixus',
  description:
    'GCC medication management market research — hospital pharmacy automation, e-prescribing, adherence programmes, Wasfaty-linked workflows, and buyer.',
  canonical: `${BASE}/gcc-medication-management-market`,
  h1: 'GCC Medication Management Market: Pharmacy, Automation & Adherence Intelligence',
  intro: [
    'The GCC medication management market covers hospital pharmacy automation, e-prescribing and closed-loop medication systems, and adherence / patient-support programmes that sit between IT, pharmacy, and clinical care. BioNixus researches chief pharmacists, hospital CIOs, and ambulatory stakeholders so vendors know which Gulf buyers fund automation versus adherence software — and what evidence they demand.',
    'Buyers searching “GCC medication management” or “Wasfaty pharmacy automation” need procurement calendars, integration requirements, and chief-pharmacist objection libraries — not generic digital-health trend decks. We scope research by decision cell (inpatient ADC, ambulatory e-Rx, adherence SaaS) before fieldwork so vendor teams do not average incompatible buyer sets across Saudi MOH networks and UAE private hospital groups.',
    'Medication-error reduction targets under Vision 2030 and UAE quality agendas create budget lines for closed-loop systems — but only when vendors prove workflow fit, training burden, and cybersecurity readiness. BioNixus validates those claims with the stakeholders who experience go-live friction, not slide-deck promises alone.',
    'Employer-sponsored adherence programmes and payer chronic-care initiatives represent a parallel funding route from hospital capex. Vendors entering the Gulf should map both channels: a winning ADC tender does not automatically unlock ambulatory adherence contracts, and vice versa.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'Hospital pharmacy automation research', detail: 'ADC, unit-dose, and compounding workflow adoption barriers.' },
    { name: 'E-prescribing / closed-loop meds', detail: 'HIS integration and clinician workflow friction.' },
    { name: 'Wasfaty and retail pharmacy linkage', detail: 'Saudi ambulatory medication management dynamics.' },
    { name: 'Adherence programme effectiveness', detail: 'What employers, payers, and hospitals will sponsor.' },
    { name: 'Procurement and tender mapping', detail: 'Capital vs SaaS buying routes across Gulf hospitals.' },
    { name: 'Safety and shortage-use cases', detail: 'Error-reduction and inventory claims that survive diligence.' },
  ],
  demandDrivers: {
    heading: 'Demand drivers',
    drivers: [
      { title: 'Hospital mega-projects', detail: 'New facilities prefer modern pharmacy workflows from day one.' },
      { title: 'Medication-error reduction targets', detail: 'Quality agendas fund closed-loop initiatives.' },
      { title: 'Pharmacy workforce pressure', detail: 'Automation pitched as staffing leverage faces culture filters.' },
      { title: 'Chronic disease burden', detail: 'Adherence and refill management rise on payer agendas.' },
      { title: 'National e-health programmes', detail: 'Integration standards shape vendor shortlists.' },
      { title: 'High-cost specialty drugs', detail: 'Inventory and cold-chain visibility become tender criteria.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'Medication management sits across capital pharmacy automation and software/adherence layers. BioNixus scopes the decision cell first — inpatient automation, ambulatory e-Rx, or adherence — before fieldwork.',
      'Saudi Wasfaty-linked ambulatory workflows, UAE private-hospital closed-loop pilots, and Kuwait/Qatar compact hospital networks each follow different procurement rhythms. A single “GCC” deck rarely survives chief-pharmacist diligence without country-specific evidence packs.',
      'BioNixus standard engagements deliver three artefacts: a stakeholder map with decision rights by country, an integration and training-burden evidence pack, and a procurement calendar aligned to capital versus SaaS funding routes. That shape keeps vendor teams from conflating inpatient automation wins with ambulatory adherence contracts.',
      'Reference-hospital packages should be validated with chief pharmacists and nursing leadership before RFP release — not assembled from global case studies alone. We interview Gulf stakeholders who have lived through failed go-lives as well as successful rollouts.',
    ],
  },
  calendarBlocks: {
    heading: '2026 GCC medication-management planning checkpoints',
    items: [
      {
        period: 'Q1 2026 — integration readiness',
        detail:
          'Map HIS/LIS interfaces, cybersecurity review gates, and bilingual training requirements before capital committees meet. Run CIO and chief-pharmacist objection interviews on connectivity claims.',
      },
      {
        period: 'Q2 2026 — hospital automation tenders',
        detail:
          'Peak window for ADC, unit-dose, and compounding automation RFPs in Saudi Vision 2030 hospitals and UAE private groups. Test TCO and service-contract narratives with procurement.',
      },
      {
        period: 'Q3 2026 — Wasfaty & ambulatory scale-up',
        detail:
          'Measure whether e-prescribing and adherence modules convert from pilot to network-wide rollout. Identify pharmacist substitution and patient-support funding barriers.',
      },
      {
        period: 'Q4 2026 — 2027 budget locking',
        detail:
          'Re-forecast SaaS versus capex mix as hospitals lock 2027 digital-health budgets. Prioritise evidence gaps that block renewal or expansion.',
      },
    ],
  },
  signalGrid: {
    heading: 'Country signals',
    items: [
      { label: 'Saudi Arabia', signal: 'Wasfaty, Vision 2030 hospitals, and large MOH networks drive ambulatory and inpatient programmes.' },
      { label: 'United Arab Emirates', signal: 'Private hospital groups and insurance pressures accelerate closed-loop and adherence pilots.' },
      { label: 'Kuwait / Qatar', signal: 'Compact hospital systems can standardise quickly when leadership sponsors change.' },
      { label: 'Oman / Bahrain', signal: 'Selective modernisation projects; localisation and service support weigh heavily.' },
    ],
  },
  audiences: [
    { audience: 'Chief pharmacists', description: 'Clinical and operational owners of medication systems.' },
    { audience: 'Hospital CIO / IT', description: 'Integration and cybersecurity gatekeepers.' },
    { audience: 'Quality / patient-safety leads', description: 'Error-reduction business-case sponsors.' },
    { audience: 'Payers & ambulatory programmes', description: 'Adherence and chronic-care funding stakeholders.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/gcc-pharmacy-market', label: 'GCC pharmacy market' },
    { to: '/gcc-generic-pharmaceuticals-market', label: 'GCC generic pharmaceuticals market' },
    { to: '/gcc-functional-service-providers-market', label: 'GCC FSP market' },
    { to: '/healthcare-market-research/saudi-arabia', label: 'Healthcare market research Saudi Arabia' },
    { to: '/blog/nupco-saudi-arabia-tendering-guide', label: 'NUPCO tendering guide' },
    { to: '/healthcare-market-research', label: 'Healthcare market research hub' },
  ],
  faqs: [
    {
      question: 'What is included in the GCC medication management market?',
      answer:
        'Hospital pharmacy automation, e-prescribing and closed-loop medication systems, inventory visibility, and adherence / patient-support programmes — researched through pharmacy, IT, and clinical stakeholders across Gulf markets.',
    },
    {
      question: 'How does Wasfaty affect medication management in Saudi Arabia?',
      answer:
        'Wasfaty expands ambulatory e-prescribing and pharmacy linkage across MOH networks — raising demand for integrated medication-management platforms that connect hospital formularies, retail pharmacies, and patient adherence programmes. BioNixus researches chief-pharmacist readiness and IT integration barriers specific to Wasfaty rollouts.',
    },
    {
      question: 'Who buys pharmacy automation versus adherence software in the GCC?',
      answer:
        'Hospital chief pharmacists and biomedical engineering typically own ADC and closed-loop capital decisions; CIOs gate integration; payers and employer programmes fund adherence SaaS. BioNixus maps these coalitions before vendor positioning.',
    },
    {
      question: 'What evidence do Gulf hospitals require for medication-error reduction claims?',
      answer:
        'Quality and patient-safety committees expect peer-reviewed error-reduction data, workflow simulations, and training-burden assessments — not marketing slogans. BioNixus validates claims with pharmacy and nursing stakeholders who experience go-live friction.',
    },
    {
      question: 'Can BioNixus research medication management across multiple GCC countries?',
      answer:
        'Yes — harmonised modules cover Saudi Arabia, UAE, Kuwait, Qatar, Oman, and Bahrain with country-specific procurement and integration overlays. Programmes link to the healthcare market research hub and NUPCO tender intelligence where hospital pull-through matters.',
    },
    {
      question: 'What is the difference between pharmacy automation and adherence software in Gulf hospitals?',
      answer:
        'Pharmacy automation (ADC, unit-dose, compounding robotics) is typically a capital decision owned by chief pharmacists and biomedical engineering with multi-year service contracts. Adherence and patient-support software is often funded by payers, employers, or ambulatory programmes with SaaS economics. Vendors who pitch both as one “medication management platform” fail chief-pharmacist diligence when integration evidence is thin. BioNixus separates buyer coalitions before positioning.',
    },
    {
      question: 'How do UAE private hospitals evaluate closed-loop medication systems?',
      answer:
        'UAE private groups (Mediclinic, NMC, Aster, Burjeel networks) evaluate closed-loop e-prescribing against DHA and DOH digital-health standards, nurse training burden, and cybersecurity review. Pilots in one hospital do not automatically roll out cluster-wide — BioNixus measures post-pilot expansion criteria with CIO and nursing leadership.',
    },
    {
      question: 'What integration evidence do Gulf CIOs require for medication-management platforms?',
      answer:
        'HIS/LIS interfaces, HL7/FHIR readiness, bilingual clinician workflows, offline failover, and audit trails for controlled substances are standard diligence items. Cybersecurity questionnaires now gate tenders as often as clinical claims. BioNixus interviews IT architecture owners to test whether vendor integration decks survive real hospital stacks.',
    },
    {
      question: 'How does specialty-drug inventory visibility affect medication management tenders?',
      answer:
        'Oncology, biologics, and cold-chain injectables require inventory visibility, temperature monitoring, and dual-source policies in Gulf hospital pharmacies. Tender specifications increasingly bundle ADC placement with specialty-drug stewardship. BioNixus researches which claims hospital pharmacists treat as mandatory versus marketing.',
    },
    {
      question: 'When should vendors run medication-management research relative to hospital capital cycles?',
      answer:
        'Capital committees typically lock automation budgets in Q4 for the following fiscal year across Gulf health systems. Evidence and reference-hospital packages should be ready one to two quarters before RFP release. BioNixus maps country-specific procurement calendars — Saudi Vision 2030 hospital openings differ from UAE private-group refresh cycles.',
    },
    {
      question: 'How does Kuwait or Qatar medication management differ from Saudi scale?',
      answer:
        'Kuwait and Qatar operate compact hospital systems where a single CIO or chief-pharmacist coalition can standardise quickly — but also reverse decisions if integration fails. Smaller networks mean fewer reference sites, so each pilot outcome is disproportionately visible. BioNixus adjusts sample design for compact markets rather than importing Saudi-only playbooks.',
    },
    {
      question: 'What role do nursing unions and workflow committees play in GCC adoption?',
      answer:
        'OR and ward nursing committees often veto medication-system changes that add steps or documentation burden — even when pharmacy and IT sponsor the project. BioNixus includes nursing leadership in workflow research so vendors quantify training time, alert fatigue, and workaround risk before capital committees commit.',
    },
    {
      question: 'How do Oman and Bahrain medication-management markets compare to KSA and UAE?',
      answer:
        'Oman and Bahrain run selective modernisation programmes with smaller hospital networks — localisation, service support, and reference-site credibility weigh more heavily than in Saudi mega-tenders. Vendors should not assume a KSA win transfers automatically; BioNixus runs country-specific chief-pharmacist and CIO modules.',
    },
    {
      question: 'What cybersecurity evidence do Gulf hospitals require for e-prescribing?',
      answer:
        'Penetration-test summaries, role-based access controls, audit trails for controlled substances, and business-continuity plans are standard IT diligence items alongside clinical claims. Failures on cybersecurity review often block tenders before pharmacy committees evaluate clinical benefits — BioNixus interviews CIO architecture owners to test vendor readiness.',
    },
    {
      question: 'Can BioNixus benchmark medication-management vendors across Gulf hospitals?',
      answer:
        'Yes — win/loss and objection modules compare incumbent ADC, e-Rx, and adherence platforms using chief-pharmacist and CIO interviews, not syndicated share estimates. Benchmarks are scoped to institution type and country so vendors receive actionable switch or defence themes.',
    },
  ],
  areaServed: ['Saudi Arabia', 'United Arab Emirates', 'Kuwait', 'Qatar', 'Oman', 'Bahrain'],
  geoAnswerBlock: {
    question: 'What is the GCC medication management market in 2026?',
    answer:
      'The GCC medication management market covers hospital pharmacy automation, e-prescribing, closed-loop medication systems, and adherence programmes across Saudi Arabia, UAE, Kuwait, Qatar, Oman, and Bahrain. BioNixus researches chief pharmacists, CIOs, and ambulatory stakeholders to map Wasfaty-linked workflows, integration requirements, and procurement calendars.',
    points: [
      {
        title: 'Hospital pharmacy automation',
        description:
          'ADC, unit-dose, and compounding robotics — capital decisions owned by chief pharmacists and biomedical engineering with multi-year service contracts.',
      },
      {
        title: 'Wasfaty & ambulatory e-Rx',
        description:
          'Saudi MOH ambulatory prescribing linkage drives demand for integrated medication-management platforms connecting hospitals and retail pharmacies.',
      },
      {
        title: 'Closed-loop & error reduction',
        description:
          'Quality agendas fund closed-loop initiatives when vendors prove workflow fit, training burden, and cybersecurity readiness with nursing and IT stakeholders.',
      },
      {
        title: 'Adherence & patient support',
        description:
          'Payer and employer-funded programmes parallel hospital capex — BioNixus separates buyer coalitions before vendor positioning.',
      },
    ],
    summary:
      'Request a GCC medication management research briefing through BioNixus contact — scoped to inpatient automation, ambulatory e-Rx, or adherence programmes.',
  },
  methodologySection: {
    heading: 'How BioNixus researches GCC medication management',
    paragraphs: [
      'Every engagement begins with a decision memo: inpatient automation, ambulatory e-prescribing, or adherence SaaS — and which Gulf countries matter for the next 12–18 months. That scope prevents averaging incompatible buyer sets before fieldwork starts.',
      'Recruitment targets verified chief pharmacists, hospital CIOs, biomedical engineering, quality and patient-safety leads, and payer-adjacent ambulatory stakeholders. Quotas reflect institution type — MOH network, private group, employer programme — not job titles alone.',
      'Instruments combine structured interviews and selective quant modules when trade-offs must be ranked under realistic cognitive-load budgets. Integration, cybersecurity, training burden, and TCO claims are tested with the stakeholders who veto go-live — not assumed from vendor decks.',
      'Deliverables include stakeholder maps with decision rights, procurement calendars aligned to capital versus SaaS cycles, objection libraries ranked by gate, and executive summaries linking findings to commercial KPI owners. Reproducible appendix layers support governance and alliance diligence.',
      'Programmes link to the healthcare market research hub, GCC pharmacy market pages, and NUPCO tender intelligence when hospital pull-through determines commercial success.',
    ],
  },
  priority: 'next',
};

const doxorubicinMarket: SpecialtyMarketDemandContent = {
  slug: 'doxorubicin-market',
  segmentLabel: 'Doxorubicin Market Access',
  badge: 'Global / GCC · Oncology Access',
  breadcrumbLabel: 'Doxorubicin Market Access',
  title: 'Doxorubicin Market Access Research | BioNixus',
  description:
    'Doxorubicin market access research — liposomal vs conventional use, oncology protocols, hospital tender dynamics, and GCC supportive oncology intelligence.',
  canonical: `${BASE}/doxorubicin-market`,
  h1: 'Doxorubicin Market Access: Protocol, Tender & Formulation Intelligence',
  intro: [
    'The doxorubicin market is protocol- and tender-shaped: formulation choice (conventional vs liposomal), cardiotoxicity management, and hospital purchasing determine real utilisation more than awareness campaigns. BioNixus researches oncologists, oncology pharmacists, and tender stakeholders — including Gulf hospital settings — to map where brands and formulations win line placement.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'Protocol and line-of-therapy research', detail: 'Where doxorubicin remains foundational versus displaced by newer regimens.' },
    { name: 'Liposomal vs conventional preference', detail: 'Cardiotoxicity, convenience, and access barriers by formulation.' },
    { name: 'Hospital formulary / tender modules', detail: 'Award criteria and substitution behaviour for oncology injectables.' },
    { name: 'Supportive-care adjacency', detail: 'How FN and cardioprotection practice interact with doxorubicin use.' },
    { name: 'Competitive analogue libraries', detail: 'Messaging themes that defend or erode share.' },
    { name: 'GCC framework cycles', detail: 'NUPCO and hospital pull-through for listed oncology injectables.' },
  ],
  demandDrivers: {
    heading: 'Demand drivers',
    drivers: [
      { title: 'Enduring protocol roles', detail: 'Breast, sarcoma, and lymphoma regimens keep baseline demand.' },
      { title: 'Formulation competition', detail: 'Liposomal products compete on safety and access, not only price.' },
      { title: 'Tender and biosimilar pressure', detail: 'Hospital pharmacies switch aggressively after awards.' },
      { title: 'Cardiotoxicity stewardship', detail: 'Monitoring capacity and guidelines reshape regimen choice.' },
      { title: 'Combination innovation', detail: 'Partner regimens can expand or shrink doxorubicin exposure.' },
      { title: 'Supply reliability', detail: 'Shortage history influences dual-source policies.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'Doxorubicin utilisation is oncology-network and hospital-pharmacy governed. BioNixus scopes by indication cluster and geography, and separates clinical preference from tender economics.',
    ],
  },
  audiences: [
    { audience: 'Medical oncologists', description: 'Protocol decision owners.' },
    { audience: 'Oncology pharmacists', description: 'Formulary and substitution influencers.' },
    { audience: 'Cardiology / cardio-oncology', description: 'Safety pathway stakeholders.' },
    { audience: 'Procurement / tenders', description: 'Framework and award decision makers.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/febrile-neutropenia-market', label: 'Febrile neutropenia market' },
    { to: '/mek-inhibitors-market', label: 'MEK inhibitors market access' },
    { to: '/italy-oncology-antiinfective-market-access', label: 'Italy oncology & anti-infective market access' },
    { to: '/gcc-generic-injectables-market', label: 'GCC generic injectables market' },
    { to: '/healthcare-market-research/therapy/oncology', label: 'Oncology market research' },
    { to: '/market-reports/gcc-oncology-market-report', label: 'GCC oncology market report' },
  ],
  faqs: [
    {
      question: 'What does doxorubicin market access research include?',
      answer:
        'Primary research with oncology and pharmacy stakeholders on formulation choice, protocol placement, cardiotoxicity practice, and hospital tender/substitution dynamics that govern real utilisation.',
    },
  ],
  priority: 'later',
};

const meaClinicalTrialImaging: SpecialtyMarketDemandContent = {
  slug: 'mea-clinical-trial-imaging-market',
  segmentLabel: 'MEA Clinical Trial Imaging',
  badge: 'Middle East & Africa · Clinical Trial Imaging',
  breadcrumbLabel: 'MEA Clinical Trial Imaging Market',
  title: 'Middle East & Africa Clinical Trial Imaging Market | BioNixus',
  description:
    'Middle East and Africa clinical trial imaging market research — central reads, site imaging capability, oncology and CNS endpoints, and sponsor/CRO buyer.',
  canonical: `${BASE}/mea-clinical-trial-imaging-market`,
  h1: 'Middle East & Africa Clinical Trial Imaging Market Intelligence',
  intro: [
    'The Middle East and Africa clinical trial imaging market is defined by site scanner readiness, central-read vendor selection, and protocol endpoint complexity — not radiology equipment sales alone. BioNixus researches sponsors, CROs, imaging core labs, and high-enrolment sites across GCC and selected African hubs to show where imaging capability unlocks country inclusion versus where it becomes a startup bottleneck.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'Site imaging capability audits', detail: 'Modality availability, technician training, and de-identification workflows.' },
    { name: 'Central-read vendor research', detail: 'Sponsor criteria for MEA-capable imaging core labs.' },
    { name: 'Oncology / CNS endpoint feasibility', detail: 'RECIST and specialised reads that strain regional capacity.' },
    { name: 'Startup timeline mapping', detail: 'Where imaging qualification delays country activation.' },
    { name: 'Data transfer & privacy diligence', detail: 'Cross-border imaging data handling expectations.' },
    { name: 'CRO / FSP interface research', detail: 'How imaging vendors fit modular Gulf and Africa delivery models.' },
  ],
  demandDrivers: {
    heading: 'Demand drivers',
    drivers: [
      { title: 'Gulf trial expansion', detail: 'More oncology and specialty trials need reliable imaging chains.' },
      { title: 'Endpoint complexity', detail: 'Advanced reads raise the bar for site qualification.' },
      { title: 'Centralisation of reads', detail: 'Sponsors prefer fewer core labs with MEA logistics proven.' },
      { title: 'Africa enrolment strategies', detail: 'Imaging readiness becomes a binding feasibility constraint.' },
      { title: 'Regulatory scrutiny', detail: 'Inspection readiness extends to imaging SOPs and archives.' },
      { title: 'Hybrid trial designs', detail: 'Decentralised elements still depend on quality imaging sites.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'Clinical trial imaging in MEA is a services market layered on hospital radiology capacity. BioNixus separates site feasibility from central-read vendor selection so sponsors do not confuse equipment presence with trial readiness.',
    ],
  },
  signalGrid: {
    heading: 'Regional signals',
    items: [
      { label: 'GCC hubs', signal: 'Strongest scanner density and growing oncology trial mix; qualification still uneven by hospital.' },
      { label: 'Egypt / North Africa', signal: 'Enrolment scale with variable imaging SOP maturity across centres.' },
      { label: 'Sub-Saharan selected hubs', signal: 'Strategic sites for specific programmes; imaging often the critical path.' },
      { label: 'Central-read vendors', signal: 'Global vs regional capability claims require primary validation with sites.' },
    ],
  },
  audiences: [
    { audience: 'Sponsor imaging / clinical ops', description: 'Vendor and country-feasibility decision owners.' },
    { audience: 'CRO imaging leads', description: 'Delivery partners balancing site load and central reads.' },
    { audience: 'Site radiology / PI teams', description: 'Operational owners of scan quality and timelines.' },
    { audience: 'Imaging core labs', description: 'Competitors seeking MEA expansion intelligence.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/gcc-clinical-trials-market', label: 'GCC clinical trials market' },
    { to: '/gcc-functional-service-providers-market', label: 'GCC FSP market' },
    { to: '/italy-clinical-trials-market', label: 'Italy clinical trials market' },
    { to: '/healthcare-market-research', label: 'Healthcare market research hub' },
    { to: '/real-world-evidence', label: 'Real world evidence' },
    { to: '/gcc-pharma-market-report-2026', label: 'GCC pharmaceutical market report 2026' },
  ],
  faqs: [
    {
      question: 'What is the Middle East and Africa clinical trial imaging market?',
      answer:
        'The services and capability ecosystem for qualifying trial sites, transferring imaging data, and delivering central reads for protocols run in GCC, North Africa, and selected Sub-Saharan hubs — researched through sponsors, CROs, core labs, and sites.',
    },
  ],
  priority: 'later',
};

export const SPECIALTY_MARKET_DEMAND_CONTENT: SpecialtyMarketDemandContent[] = [
  singaporeMedtechManufacturing,
  singaporePharmaceuticalMarket,
  japanGeneralSurgicalDevices,
  healthcareBioconvergence,
  nupcoTenderCalendar,
  singaporeIvdMarketAccess,
  japanNeurologyDevices,
  japanMedicalDisposables,
  japanMedtechAccessAutomation,
  italyClinicalTrials,
  mekInhibitors,
  febrileNeutropenia,
  italyPortableDiagnostics,
  italyDeviceConnectivity,
  italyOncologyAntiInfectiveAccess,
  gccFspMarket,
  gccMedicationManagement,
  doxorubicinMarket,
  meaClinicalTrialImaging,
];

export const SPECIALTY_MARKET_DEMAND_BY_SLUG: Record<string, SpecialtyMarketDemandContent> =
  Object.fromEntries(SPECIALTY_MARKET_DEMAND_CONTENT.map((item) => [item.slug, item]));

export function getSpecialtyMarketDemandSitemapEntries(): Array<{
  path: string;
  priority: string;
  changefreq: string;
}> {
  return SPECIALTY_MARKET_DEMAND_CONTENT.map((item) => ({
    path: `/${item.slug}`,
    priority: item.priority === 'now' ? '0.90' : item.priority === 'next' ? '0.86' : '0.84',
    changefreq: 'monthly',
  }));
}
